var title_f20_39_21104="Thoracic aortic plaque";
var content_f20_39_21104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Thoracic aortic plaque",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three transesophageal echocardiograms of the thoracic aorta: left: normal; middle: moderate (3 mm) plaque; and right: severe (7 mm) plaque.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tunick, PA, Kronzon, I. Atheroembolism. In: Vascular Medicine. A Companion to Braunwald's Heart Disease, 1st edition, Dzau, VJ, Creager, M, Loscalzo, J, et al (Eds), WB Saunders 2005. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21104=[""].join("\n");
var outline_f20_39_21104=null;
var title_f20_39_21105="Two rescuer bag pediatric";
var content_f20_39_21105=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two rescuer bag-mask ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two rescuers may be necessary to provide ventilation. One rescuer may need both hands to open the airway and make the seal between the child's face and the mask. The second rescuer is then needed to provide positive pressure ventilation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21105=[""].join("\n");
var outline_f20_39_21105=null;
var title_f20_39_21106="Melanoma nail dystrophy";
var content_f20_39_21106=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Nail melanoma in situ",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21106=[""].join("\n");
var outline_f20_39_21106=null;
var title_f20_39_21107="Hemin: Drug information";
var content_f20_39_21107=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hemin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/20/18755?source=see_link\">",
"    see \"Hemin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Panhematin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F178703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Modifiers;",
"     </li>",
"     <li>",
"      Blood Product Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F178697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Porphyria (AIP): I.V.: 1-4 mg/kg/day administered over 10-15 minutes for 3-14 days; may be repeated no earlier than every 12 hours; not to exceed 6 mg/kg in any 24-hour period",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3053516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Porphyria (AIP): Children &ge;16 years: I.V.: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F178698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F178691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Panhematin&reg;: 313 mg [contains natural rubber/natural latex in packaging; provides 7 mg/mL when reconstituted]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Panhematin&reg;: 313 mg [DSC] [provides 7 mg/mL when reconstituted]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F178683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3053517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse over 10-15 minutes using a 0.45 micron or smaller filter. Administer through a large vein or central line to prevent phlebitis.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F178692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of recurrent attacks of acute intermittent porphyria (AIP)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F178701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Pyrexia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Coagulopathy, fibrin split products increased, hematocrit decreased, hypofibrogenemia, prothrombin time increased, partial thromboplastin time increased, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F178694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hemin or any component of the formulation; porphyria cutanea tarda",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3053197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Should only be used after an appropriate period of alternate therapy (carbohydrate loading) has been tried.",
"     </b>",
"     Intended to prevent porphyria attacks from becoming critical; not intended to repair neuronal damage resulting from attacks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;16 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to Ovation Pharmaceuticals at 1-800-455-1141.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Packaging may contain natural latex rubber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of a physician experienced in the management of porphyrias.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3053193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3053194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit out weighs the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3053196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16570872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     It is not known if hemin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering hemin to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Panhematin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     313 mg (1): $5997.01",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3053519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinary levels of  delta-aminolevulinic acid (ALA), uroporphyrinogen (UPG), porphobilinogen (PBG), coproporphyrin",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4041594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Human Hemin Orphan Europe (PL);",
"     </li>",
"     <li>",
"      Normosang (CH, CZ, DK, EE, FI, GB, SE);",
"     </li>",
"     <li>",
"      Panhematin (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3053514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits the hepatic and/or marrow synthesis of ALA synthase, the enzyme that regulates the porphyrin/heme pathway",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson KE, Bloomer JR, Bonkovsky HL, et al, &ldquo;Recommendations for the diagnosis and Treatment of the Acute Porphyrias,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2005, 142(6):439-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/39/21107/abstract-text/15767622/pubmed\" id=\"15767622\" target=\"_blank\">",
"        15767622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8970 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-AFBC45AB80-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21107=[""].join("\n");
var outline_f20_39_21107=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708897\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178696\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178703\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178697\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053516\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178698\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897444\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897445\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178691\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178683\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053517\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178692\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178701\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178694\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053197\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299437\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220760\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053193\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053194\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053196\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570872\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323180\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053519\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4041594\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053514\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8970\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8970|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/20/18755?source=related_link\">",
"      Hemin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_39_21108="Cephalexin: Patient drug information";
var content_f20_39_21108=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cephalexin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     see \"Cephalexin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/5/30804?source=see_link\">",
"     see \"Cephalexin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Keflex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cephalex&reg;;",
"     </li>",
"     <li>",
"      Dom-Cephalexin;",
"     </li>",
"     <li>",
"      Keflex&reg;;",
"     </li>",
"     <li>",
"      Novo-Lexin;",
"     </li>",
"     <li>",
"      Nu-Cephalex;",
"     </li>",
"     <li>",
"      PMS-Cephalexin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cephalexin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension, children's suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699479",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) in a refrigerator. Throw away any part not used after 2 weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11936 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21108=[""].join("\n");
var outline_f20_39_21108=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148610\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148611\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015352\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015351\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015356\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015357\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015359\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015354\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015355\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015360\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015361\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=related_link\">",
"      Cephalexin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/5/30804?source=related_link\">",
"      Cephalexin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_39_21109="Beclomethasone (nasal): Drug information";
var content_f20_39_21109=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Beclomethasone (nasal): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/51/16180?source=see_link\">",
"    see \"Beclomethasone (nasal): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/34/7716?source=see_link\">",
"    see \"Beclomethasone (nasal): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7990246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Beconase AQ&reg;;",
"     </li>",
"     <li>",
"      Qnasl&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7990247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Beclomethasone&reg;;",
"     </li>",
"     <li>",
"      Mylan-Beclo AQ;",
"     </li>",
"     <li>",
"      Nu-Beclomethasone;",
"     </li>",
"     <li>",
"      Rivanase AQ",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7990284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Nasal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7991818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Allergic rhinitis:",
"     </b>",
"     Inhalation, nasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Beconase&reg; AQ: 1-2 inhalations each nostril twice daily (total dose: 168-336 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Qnasl&trade;: Two inhalations each nostril once daily (total dose: 320 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Nasal polyps (postsurgical prophylaxis), vasomotor rhinitis (Beconase AQ&reg;):",
"     </b>",
"     Inhalation, nasal: 1-2 inhalations each nostril twice daily (total dose: 168-336 mcg/day)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7991817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/34/7716?source=see_link\">",
"      see \"Beclomethasone (nasal): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Rhinitis:",
"     </b>",
"     Inhalation, nasal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children 6-11 years (Beconase&reg; AQ): Initial: One inhalation each nostril twice daily (total dose: 168 mcg/day); if response inadequate, may increase to 2 inhalations each nostril twice daily (total dose: 336 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children &ge;12 years (Beconase&reg; AQ, Qnasl&trade;): Refer to adult dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Nasal polyps (postsurgical prophylaxis):",
"     </b>",
"     Inhalation, nasal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children 6-11 years (Beconase&reg; AQ): Initial: One inhalation each nostril twice daily (total dose: 168 mcg/day); if response inadequate, may increase to 2 inhalations each nostril twice daily (total dose: 336 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children &ge;12 years (Beconase&reg; AQ): Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7991819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7991835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, intranasal, as dipropionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Qnasl&trade;: 80 mcg/inhalation (8.7 g) [contains dehydrated ethanol; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intranasal, as dipropionate [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Beconase AQ&reg;: 42 mcg/inhalation (25 g) [contains benzalkonium chloride, ethanol 0.25%; 180 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7990249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7991821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Beconase AQ&reg;: Shake well prior to each use. Prior to initial use, prime pump 6 times (or until fine spray appears); repeat priming if product not used for &ge;7 days. Spray in nostril(s); avoid spraying in eyes or mouth.  Nasal applicator and dust cap may be washed in warm water and dry thoroughly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Qnasl&trade;: Shake well prior to each use. Prior to initial use, prime pump 4 times. If product not used for &ge;7 days, prime pump 2 times. Spray in nostril(s); avoid spraying in eyes or mouth.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7990250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Beconase AQ&reg;: Symptomatic treatment of seasonal or perennial allergic rhinitis; nonallergic (vasomotor) rhinitis; prevent recurrence of nasal polyps following surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Qnasl&trade;: Symptomatic treatment of seasonal or perennial allergic rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14225098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to antibiotics in empiric treatment of acute bacterial rhinosinusitis (ABRS) (Chow, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7991708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, lightheadedness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Growth velocity reduction in children and adolescents, HPA function suppression (dose related), weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dry/irritated nose, throat and mouth, hoarseness, localized",
"     <i>",
"      Candida",
"     </i>",
"     or",
"     <i>",
"      Aspergillus",
"     </i>",
"     infection, loss of smell, loss of taste, nausea, unpleasant smell, unpleasant taste, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, epistaxis, localized",
"     <i>",
"      Candida",
"     </i>",
"     infection, nasal septum perforation (rare), nasal stuffiness, nosebleeds, rhinorrhea, sneezing, transient irritation, ulceration of nasal mucosa (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts (rare), glaucoma (rare), intraocular pressure increased (rare), tearing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, paradoxical bronchospasm (rare), pharyngitis, sinusitis, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic/anaphylactoid reactions, immediate and delayed hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7991691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to beclomethasone or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7991692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic steroid needed to treat patients having trauma, surgery, or infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Delayed wound healing: Avoid nasal corticosteroid use in patients with recent nasal septal ulcers, nasal surgery or nasal trauma until healing has occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions (including anaphylaxis, angioedema, rash, and urticaria) have been reported; discontinue for severe reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infections, mask an acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines; avoid exposure to chickenpox and/or measles, especially if not immunized. Avoid use or use with caution in patients with latent/active tuberculosis, untreated bacterial or fungal infections (local or systemic), viral or parasitic infections, or  ocular herpes simplex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Local nasal effects: Nasal septal perforation and localized Candida albicans infections of the nose and/or pharynx may occur (rarely).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with intranasal corticosteroid use; use with caution in patients with a history of increased intraocular pressure, cataracts and/or glaucoma. Consider routine eye exams in chronic users or in patients who report visual changes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range: 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of  intranasal corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9770054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7991686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7991687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies following SubQ administration but not with oral inhalation. A decrease in fetal growth has not been observed with inhaled corticosteroid use during pregnancy. Inhaled corticosteroids are recommended for the treatment of allergic rhinitis during pregnancy (NAEPP,  2005).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7991689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7991690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Other corticosteroids have been found in breast milk; however, information for beclomethasone is not available. Use of inhaled corticosteroids is not a contraindication to breast-feeding (NAEPP, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7991837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (Qnasl Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mcg/ACT (8.7 g): $139.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Beconase AQ Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     42 mcg/spray (25 g): $195.78",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14049713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Growth (adolescents and children); signs/symptoms of HPA axis suppression/adrenal insufficiency; ocular changes",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      AeroBec (NO);",
"     </li>",
"     <li>",
"      Afifon (IL);",
"     </li>",
"     <li>",
"      Alanase (NZ);",
"     </li>",
"     <li>",
"      Aldecin (BG, NZ);",
"     </li>",
"     <li>",
"      Atomase (NZ);",
"     </li>",
"     <li>",
"      Beclate (HK, IN, MY, ZA);",
"     </li>",
"     <li>",
"      Beclo-Rhino (FR);",
"     </li>",
"     <li>",
"      Becloforte (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Beclomet (CH, DE, MY, NO, SG, TW);",
"     </li>",
"     <li>",
"      Beclonasal (EE, FI);",
"     </li>",
"     <li>",
"      Beclorhinol (DE);",
"     </li>",
"     <li>",
"      Beclosol Aquoso (BR);",
"     </li>",
"     <li>",
"      Beconase (AE, AT, BB, BF, BH, BJ, BM, BS, CH, CI, CL, CO, CR, CY, DK, DO, EE, EG, ET, FI, FR, GB, GH, GM, GN, GT, GY, HN, IE, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PK, PR, PT, QA, SA, SC, SD, SL, SN, SV, SY, TH, TN, TT, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Beconase Allergy &amp; Hayfever 12 Hour (AU);",
"     </li>",
"     <li>",
"      Becotide (AE, BE, BF, BG, BH, BJ, CI, CY, CZ, EG, ET, GH, GM, GN, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, NO, OM, QA, RU, SA, SC, SD, SE, SK, SL, SN, SY, TN, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Belax (MY);",
"     </li>",
"     <li>",
"      Bemase (TH);",
"     </li>",
"     <li>",
"      Ciplametazon Inhalador Nasal (CO);",
"     </li>",
"     <li>",
"      Clenil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, TW, YE);",
"     </li>",
"     <li>",
"      Clenil Forte (ID);",
"     </li>",
"     <li>",
"      Clenil Nasal (BR);",
"     </li>",
"     <li>",
"      Clipper (BE);",
"     </li>",
"     <li>",
"      Decomit (SG);",
"     </li>",
"     <li>",
"      Destap (CN);",
"     </li>",
"     <li>",
"      Eclosynt (CO);",
"     </li>",
"     <li>",
"      Ecobec (BG);",
"     </li>",
"     <li>",
"      Nasair (VE);",
"     </li>",
"     <li>",
"      Nasobec (GR, HK, KP, PL);",
"     </li>",
"     <li>",
"      Oxiplus SF (PY, UY);",
"     </li>",
"     <li>",
"      Propavent Nasal (AR);",
"     </li>",
"     <li>",
"      Q Var (CH);",
"     </li>",
"     <li>",
"      Rhino Clenil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Rino Clenil (KP, TH);",
"     </li>",
"     <li>",
"      Rinosol (AR, PY);",
"     </li>",
"     <li>",
"      Viarex (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7991717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7991772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Beclomethasone dipropionate (BDP): 20 L; 17-BMP: 424 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 17-BMP: 87% to 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Prodrug; undergoes rapid conversion to 17-BMP during absorption; followed by additional metabolism via CYP3A4 to other, less active metabolites (beclomethasone-21-monopropionate [21-BMP] and beclomethasone [BOH])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 17-BMP: 44% (43% from swallowed portion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: BDP: ~0.3 hours; 17-BMP: ~4.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (60%); urine (&lt;10% to 12%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(8):e72-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/39/21109/abstract-text/22438350/pubmed\" id=\"22438350\" target=\"_blank\">",
"        22438350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Demain JG and Goetz DW, &ldquo;Pediatric Adenoidal Hypertrophy and Nasal Airway Obstruction: Reduction With Aqueous Nasal Beclomethasone,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 95(3):355-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/39/21109/abstract-text/7862473/pubmed\" id=\"7862473\" target=\"_blank\">",
"        7862473",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kobayashi RH, Tinkelman DG, Reese ME, et al, &ldquo;Beclomethasone Dipropionate Aqueous Nasal Spray for Seasonal Allergic Rhinitis in Children,&rdquo;",
"      <i>",
"       Ann Allergy",
"      </i>",
"      , 1989, 62(3):205-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/39/21109/abstract-text/2646995/pubmed\" id=\"2646995\" target=\"_blank\">",
"        2646995",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8871 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-0E8BE10A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21109=[""].join("\n");
var outline_f20_39_21109=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990246\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990247\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990284\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991818\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991817\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991819\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673277\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673278\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991835\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990249\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991821\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990250\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14225098\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991708\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991691\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991692\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298818\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770054\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991686\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991687\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991689\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991690\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991837\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14049713\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961957\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991717\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991772\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8871\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8871|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/51/16180?source=related_link\">",
"      Beclomethasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/34/7716?source=related_link\">",
"      Beclomethasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30199?source=related_link\">",
"      Beclomethasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/17/26901?source=related_link\">",
"      Beclomethasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/13/44245?source=related_link\">",
"      Beclomethasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_39_21110="Iron sucrose: Pediatric drug information";
var content_f20_39_21110=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iron sucrose: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"    see \"Iron sucrose: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/41/29331?source=see_link\">",
"    see \"Iron sucrose: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Venofer&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Venofer&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1020337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Iron Salt, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Mineral, Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F15852436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Multiple forms for parenteral iron exist; close attention must be paid to the specific product when ordering and administering",
"     </b>",
"     ; incorrect selection or substitution of one form for another without proper dosage adjustment may result in serious over- or under-dosing.  Doses are expressed as mg of",
"     <b>",
"      elemental iron",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anemia of prematurity:",
"     </b>",
"     Limited data available: I.V.: 1 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     infused over 2 hours; dosing based on results of a small comparative trial with oral iron therapy and erythropoietin which included 29 premature neonates (GA &lt;31 weeks; treatment group, n=10) who at the time of treatment initiation had a mean age of 23.3 &plusmn; 2.9 days, and mean weight of 1266 &plusmn; 81 g; higher reticulocyte counts and fewer transfusions were observed in the parenteral iron group compared to the oral treatment arm; due to potential oxidative injury risk in smaller, less stable premature neonates, the authors suggest that lower doses should be considered (Pollock, 2001; Pollock, 2001a).  Further studies are needed.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1020366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"      see \"Iron sucrose: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Multiple forms for parenteral iron exist; close attention must be paid to the specific product when ordering and administering",
"     </b>",
"     ; incorrect selection or substitution of one form for another without proper dosage adjustment may result in serious over- or underdosing.  Doses are expressed as mg of",
"     <b>",
"      elemental iron",
"     </b>",
"     .",
"     <b>",
"      Note:",
"     </b>",
"     Per National Kidney Foundation DOQI Guidelines, initiation of iron therapy, determination of dose, and duration of therapy should be guided by results of iron status tests combined with the Hb level and the dose of the erythropoietin stimulating agent. See Reference Range for target levels. There is insufficient evidence to recommend I.V. iron if ferritin level &gt;500 ng/mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Iron deficiency anemia in CKD:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Repletion treatment:",
"     </i>",
"     Limited data available: Children &ge;2 years and Adolescents &lt;15 years: I.V.: 1 mg/kg/dialysis; dosing based on a dose-finding trial in 14 pediatric patients and successfully increased ferritin therapeutic levels; iron overload (serum ferritin &gt;400 ng/mL) was reported with the higher dose used in the study (3 mg/kg/dialysis) (Leijn, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Maintenance therapy:",
"     </i>",
"     Children &ge;2 years and Adolescents: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Hemodialysis-dependent CKD: 0.5 mg/kg/dose (maximum dose: 100 mg) every 2 weeks for 12 weeks (6 doses); may repeat if clinically indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Peritoneal dialysis-dependent CKD; concurrent erythropoietin therapy: 0.5 mg/kg/dose (maximum dose: 100 mg) every 4 weeks for 12 weeks (3 doses); may repeat if clinically indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nondialysis-dependent CKD; concurrent erythropoietin therapy: 0.5 mg/kg/dose (maximum dose: 100 mg) every 4 weeks for 12 weeks (3 doses); may repeat if clinically indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Nonrenal iron deficiency anemia; treatment in patients refractory to oral therapy (eg, long-term TPN, GI malabsorption):",
"     </b>",
"     Limited data available (Norman, 2011; Pinsk, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Calculate Iron Deficit:  Total replacement dose (mg of iron) = 0.6 x weight (kg) x [100 - (actual Hgb /12 x 100)];",
"     <b>",
"      Note:",
"     </b>",
"     In this equation, 12 is the desired target Hgb concentration; in some patients, a different target may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Initial dose: I.V.: 5-7 mg/kg; maximum dose: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Maintenance dose:  I.V.: 5-7 mg/kg every 1-7 days until total replacement dose achieved; maximum single dose: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Iron deficiency anemia in CKD:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hemodialysis-dependent CKD: 100 mg administered  during consecutive dialysis sessions to  a cumulative total dose of 1000 mg (10 doses); may repeat treatment if clinically indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peritoneal dialysis-dependent  CKD: Two infusions of 300 mg administered 14 days apart, followed by a single 400 mg infusion 14 days later (total cumulative dose of 1000 mg in 3 divided doses); may repeat treatment if clinically indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nonhemodialysis-dependent CKD: 200 mg  administered on 5 different occasions within a 14-day period; cumulative total dose: 1000 mg in 14-day period.",
"     <b>",
"      Note:",
"     </b>",
"     Dosage has also been administered as two infusions of 500 mg in a maximum of 250 mL normal saline infused over 3.5-4 hours on day 1 and day 14 (limited experience); may repeat treatment if clinically indicated",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Venofer&reg;: Elemental iron 20 mg/mL (2.5 mL, 5 mL, 10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1020369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: May administer I.V.; avoid dilution of solution for infusion in dextrose due to an increased incidence of local pain and phlebitis; not for I.M. use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pediatric patients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premature neonates: Infusion: Dilute dose to 2 mg/mL in NS; infuse over at least 2 hours (Pollak, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: Dependent upon indication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     CKD treatment of iron deficiency anemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Slow I.V. injection: Administer undiluted over 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infusion: Dilute dose in 25 mL of NS; infuse over 5-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Nonrenal treatment of iron deficiency anemia: One trial reported dilution of iron dose to a final concentration of 1 mg/mL in NS and infused at 1-1.3 mL/minute (Pinsk, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Others suggest the following recommendations (Norman, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     For doses &le;100 mg, dilute dose in 100 mL NS and infuse over at least 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     For doses &gt;100 mg and &le;200 mg, dilute dose in 200 mL NS and infuse over at least 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     For doses &gt;200 mg and &le;300 mg, dilute dose in 250 mL NS and infuse over at least 90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Slow I.V. injection: May administer doses &le;200 mg undiluted by slow I.V. injection over 2-5 minutes; when administering to hemodialysis-dependent patients, give iron sucrose early during the dialysis session",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infusion: Dilute doses &le;200 mg in maximum of 100 mL NS and infuse over at least 15 minutes; dilute 300 mg in a maximum of 250 mL NS and infuse over 1.5 hours; dilute 400 mg in a maximum of 250 mL NS and  infuse over 2.5 hours; dilute 500 mg in a maximum of 250 mL NS and infuse over 3.5-4  hours (limited experience). When administering to hemodialysis-dependent patients, give iron sucrose early during the dialysis session. Do not dilute to concentrations &lt;1 mg/mL.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3071704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in TPN.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1020355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Iron sucrose is stable for 7 days at room temperature or under refrigeration when undiluted in a plastic syringe or following dilution in normal saline in a plastic syringe (2-10 mg/mL) or I.V. bag (1-2 mg/mL). The manufacturer recommends not adding to parenteral nutrition solutions; however, iron sucrose at concentrations of 0.1 mg/dL and 0.25  mg/dL in 2-in-1 parenteral nutrition solutions with neonatal-range amino acid and cysteine were shown to be stable for 24 hours; precipitation occurred at higher concentrations (ie, 1-10 mg/dL) (MacKay, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1020338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of iron deficiency anemia in hemodialysis-dependent chronic kidney disease (HDD-CKD) (FDA approved in ages &ge;2 years and adults); treatment of iron deficiency anemia with concurrent erythropoietin therapy in peritoneal dialysis-dependent (PDD) CKD and nondialysis-dependent (NDD) CKD (FDA approved in ages &ge;2 years); treatment of iron deficiency anemia in PDD-CKD and NDD-CKD (FDA approved in adults); has also been used for treatment of nonrenal iron deficiency anemia  and supplementation of iron in patients for which oral therapy is neither effective nor tolerated (eg, long-term TPN)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7897706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Iron sucrose may be confused with ferumoxytol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F184624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Events are associated with use in adults unless otherwise specified.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Cardiovascular: Arteriovenous fistula thrombosis (children), chest pain, hyper-/hypotension, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid overload, gout, hyper-/hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, peritonitis (children), vomiting, taste perversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, extremity pain, muscle cramps, myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ear pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, nasal congestion, nasopharyngitis, pharyngitis, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Graft complication, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylactic shock, anaphylactoid reactions, angioedema, bradycardia, cardiovascular collapse, hypersensitivity (including wheezing), loss of consciousness, necrotizing enterocolitis (reported in premature infants, no causal relationship established), seizure, shock, urine discoloration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1020342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to the iron formulation or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5275401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with histories of significant allergies, asthma, serious hepatic impairment, pre-existing cardiac disease (may exacerbate cardiovascular complications), and rheumatoid arthritis (may exacerbate joint pain and swelling). Discontinue oral iron prior to initiating parenteral iron therapy. Exogenous hemosiderosis may result from excess iron stores; patients with refractory anemias and/or hemoglobinopathies may be prone to iron overload with unwarranted iron supplementation. In patients with chronic kidney disease (CKD) requiring iron supplementation, the I.V. route is preferred for hemodialysis patients; either oral iron or I.V. iron may be used for nondialysis and peritoneal dialysis CKD patients. Use parenteral iron products with caution in premature neonates; necrotizing enterocolitis has been reported; however, no causal relationship established.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use caution when interchanging products [ie, generic substitution with an iron sucrose similar (ISS) preparation (not currently available in U.S.)]; an observational  trial in 75 adult hemodialysis patients reported destabilization of hemoglobin and serum iron indices, resulting in higher dose requirements (Rottembourg, 2011) after conversion to an ISS preparation. A case-series (n=3) described altered infusion tolerance and adverse effects after product conversion to an ISS preparation in nonhemodialysis adult patients; observed adverse events not previously reported in the patients included hypovolemic dysregulation, urticaria, headache, peripheral edema, and myalgia (Stein, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1020343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cases of hypersensitivity reactions, including rare postmarketing anaphylactic and anaphylactoid reactions (some fatal), have been reported; monitor patients during and for &ge;30 minutes after administration; discontinue immediately for signs/symptoms of a hypersensitivity reaction (shock, hypotension, loss of consciousness).  Equipment and medications (eg, epinephrine, steroids, diphenhydramine) for resuscitation and trained personnel experienced in handling medical emergencies should always be immediately available. Significant hypotension has been reported frequently in hemodialysis-dependent patients; may also occur in peritoneal dialysis and nondialysis patients but incidence is substantially lower.  Hypotension may be related to total dose or rate of administration; avoid rapid I.V. injection and follow recommended guidelines.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F184594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Based on limited data, iron sucrose may be effective for the treatment of iron-deficiency anemia in pregnancy. It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1020371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hematocrit, hemoglobin, serum ferritin, transferrin, percent transferrin saturation, TIBC; takes about 4 weeks of treatment to see increased serum iron and ferritin, and decreased TIBC. Serum iron concentrations should be drawn &ge;48 hours after last dose (due to rapid increase in values following administration); signs/symptoms of hypersensitivity reactions (during and &ge;30 minutes following infusion); hypotension (following infusion).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1020360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum iron:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Newborns: 110-270 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: 30-70 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 55-120 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Male: 75-175 mcg/dL; female: 65-165 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Total iron binding capacity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Newborns: 59-175 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: 100-400 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adults: 230-430 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transferrin: 204-360 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Percent transferrin saturation (TSAT): 20% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron levels &gt;300 mcg/dL may be considered toxic; should be treated as an overdosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferritin: 13-300 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chronic kidney disease (CKD): Targets for iron therapy (KDOQI Guidelines, 2007) to maintain Hgb 11-12 g/dL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: Nondialysis CKD, hemodialysis, or peritoneal dialysis: Ferritin: &gt;100 ng/mL and TSAT &gt;20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:  Nondialysis (CKD) or peritoneal dialysis: Ferritin: &gt;100 ng/mL and TSAT &gt;20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hemodialysis: Ferritin &gt;200 ng/mL and TSAT &gt;20% or CHr (content of hemoglobin in reticulocytes) &gt;29 pg/cell",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1020358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replaces iron found in hemoglobin, myoglobin, and specific enzymes; allows transportation of oxygen via hemoglobin",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5275402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Hematologic response to either oral or parenteral iron salts is essentially the same; red blood cell form and color changes within 3-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: Peak reticulocytosis occurs in 5-10 days, and hemoglobin values increase within 2-4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1020361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Following I.V. doses, the uptake of iron by the reticuloendothelial system appears to be constant at about 40-60 mg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : Healthy adults: 7.9 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism:  Dissociated into iron and sucrose by the reticuloendothelial system",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: Adolescents (nondialysis-dependent): 8 hours; adults: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Healthy adults: Urine (5%) within 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Not dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F15852498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/41/29331?source=see_link\">",
"      see \"Iron sucrose: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May experience hypotension, black stools, nausea, vomiting, or constipation; report immediately severe unresolved nausea, headache, dizziness, leg cramps, chest pain or palpations, or swelling of extremities.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F5275404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contains sucrose: 300 mg/mL",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Crary SE, Hall K, and Buchanan GR, \"Intravenous Iron Sucrose for Children With Iron Deficiency Failing to Respond to Oral Iron Therapy,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2011, 56(4):615-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/39/21110/abstract-text/21298748/pubmed\" id=\"21298748\" target=\"_blank\">",
"        21298748",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2007, 50(3):471-530.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/39/21110/abstract-text/17720528/pubmed\" id=\"17720528\" target=\"_blank\">",
"        17720528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leijn E, Monnens LA, and Cornelissen EA, \"Intravenous Iron Supplementation in Children on Hemodialysis,\"",
"      <i>",
"       J Nephrol",
"      </i>",
"      , 2004, 17(3):423-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/39/21110/abstract-text/15365964/pubmed\" id=\"15365964\" target=\"_blank\">",
"        15365964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacKay M, Rusho W, Jackson D, et al, \"Physical and Chemical Stability of Iron Sucrose in Parenteral Nutrition,\"",
"      <i>",
"       Nutr Clin Pract",
"      </i>",
"      , 2009, 24(6):733-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/39/21110/abstract-text/19955552/pubmed\" id=\"19955552\" target=\"_blank\">",
"        19955552",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Norman JL and Crill CM, \"Optimizing the Transition to Home Parenteral Nutrition in Pediatric Patients,\"",
"      <i>",
"       Nutr Clin Pract",
"      </i>",
"      , 2011, 26(3):273-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/39/21110/abstract-text/21586412/pubmed\" id=\"21586412\" target=\"_blank\">",
"        21586412",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pinsk V, Levy J, Moser A, et al, \"Efficacy and Safety of Intravenous Iron Sucrose Therapy in a Group of Children With Iron Deficiency Anemia,\"",
"      <i>",
"       Isr Med Assoc J",
"      </i>",
"      , 2008, 10(5):335-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/39/21110/abstract-text/18605353/pubmed\" id=\"18605353\" target=\"_blank\">",
"        18605353",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pollak A, Hayde M, Hayn M, et al, \"Effect of Intravenous Iron Supplementation on Erythropoiesis in Erythropoietin-Treated Premature Infants,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 107(1):78-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/39/21110/abstract-text/11134438/pubmed\" id=\"11134438\" target=\"_blank\">",
"        11134438",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pollak A, Widness JA, and Lombard KA, &ldquo;Iron Supplementation During Erythropoietin Treatment,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(6): 1390-1.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rottembourg J, Kadri A, Leonard E, et al, \"Do Two Intravenous Iron Sucrose Preparations Have the Same Efficacy?\"",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2011, 26(10):3262-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/39/21110/abstract-text/21355067/pubmed\" id=\"21355067\" target=\"_blank\">",
"        21355067",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stein J, Dignass A, and Chow KU, \"Clinical Case Reports Raise Doubts About the Therapeutic Equivalence of an Iron Sucrose Similar Preparation Compared With Iron Sucrose Originator,\"",
"      <i>",
"       Curr Med Res Opin",
"      </i>",
"      , 2012, 28(2):241-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/39/21110/abstract-text/22181342/pubmed\" id=\"22181342\" target=\"_blank\">",
"        22181342",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13058 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-201.65.114.212-EEAAC3DE18-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21110=[""].join("\n");
var outline_f20_39_21110=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184604\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184605\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020337\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15852436\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020366\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184587\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184573\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020369\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3071704\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020355\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020338\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897706\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184624\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020342\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5275401\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020343\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299545\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184581\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184583\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184594\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020371\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020360\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020358\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5275402\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020361\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15852498\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5275404\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13058\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13058|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=related_link\">",
"      Iron sucrose: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/41/29331?source=related_link\">",
"      Iron sucrose: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_39_21111="Pseudoporphyria";
var content_f20_39_21111=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pseudoporphyria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/39/21111/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/39/21111/contributors\">",
"     Craig A Elmets, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/39/21111/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/39/21111/contributors\">",
"     Maja Mockenhaupt, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/39/21111/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/39/21111/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/39/21111/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H30223457\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudoporphyria is a bullous photodermatosis with the clinical and histologic features of porphyria cutanea tarda (PCT) in the absence of abnormalities in porphyrin metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/1\">",
"     1",
"    </a>",
"    ]. Pseudoporphyria has been associated with medications, chronic renal failure and hemodialysis, and tanning beds. Patients typically present with skin fragility, bullae, milia, and scarring on the dorsum of the hands and other sun-exposed areas. Histologically, there is a noninflammatory subepidermal blister.",
"   </p>",
"   <p>",
"    This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and treatment of pseudoporphyria. PCT and other types of porphyrias associated with photosensitivity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link\">",
"     \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/51/825?source=see_link\">",
"     \"Variegate porphyria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5801?source=see_link\">",
"     \"Congenital erythropoietic porphyria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30223464\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of pseudoporphyria is unknown. It occurs at any age and more frequently in women than in men. Pseudoporphyria has been reported in approximately 10 percent of children taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , a nonsteroidal antiinflammatory drug routinely used in the therapy of juvenile idiopathic arthritis. Among children treated with naproxen, risk factors for the development of pseudoporphyria include skin phototypes I or II (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ),",
"    <span class=\"nowrap\">",
"     blue/gray",
"    </span>",
"    eyes, and the concurrent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30223471\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four factors have been implicated in the etiology of pseudoporphyria: ultraviolet (UV) radiation, medications, chronic renal failure and hemodialysis, and tanning beds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182198836\">",
"    <span class=\"h2\">",
"     UV radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the exact pathogenetic mechanism is unknown, drug-induced pseudoporphyria is considered a photodynamic phototoxic drug reaction. In this type of reaction, the photosensitizing compound, upon absorption of the appropriate wavelength radiation, changes to an excited state and reacts with oxygen to form reactive oxygen species (ROS) such as singlet oxygen,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , or superoxide anion. ROS can damage cell components such as nucleic acids, membranes, lipids, and proteins. Mediators of inflammation and inflammatory cells participate in tissue injury, including products of complement activation, proinflammatory cytokines, arachidonic acid metabolites, proteases, and polymorphonuclear leukocytes. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21925384\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudoporphyria was first identified among individuals taking the quinolone antibiotic nalidixic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Subsequently, a variety of other medications have been associated with pseudoporphyria, including nonsteroidal antiinflammatory drugs (NSAIDs), other types of antibiotics, diuretics, retinoids, and antineoplastic agents (",
"    <a class=\"graphic graphic_table graphicRef83233 \" href=\"UTD.htm?14/36/14924\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/1,8-14\">",
"     1,8-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     Naproxen",
"    </a>",
"    , a propionic acid derivative, is responsible for most cases of pseudoporphyria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/2,3,15-22\">",
"     2,3,15-22",
"    </a>",
"    ]. Propionic acid derivative NSAIDs (eg, naproxen,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30632?source=see_link\">",
"     oxaprozin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) are more likely to cause pseudoporphyria than other classes of NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/23-33\">",
"     23-33",
"    </a>",
"    ]. However, several nonpropionic acid NSAIDs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/41/25240?source=see_link\">",
"     diflunisal",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/63/41976?source=see_link\">",
"     mefenamic acid",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"     nabumetone",
"    </a>",
"    ) have also been associated with pseudoporphyria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/23,24,26,27,33,34\">",
"     23,24,26,27,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unknown why pseudoporphyria manifests with vesicles and bullae, whereas drug induced phototoxic reactions usually appear as exaggerated sunburns [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/7,21,35\">",
"     7,21,35",
"    </a>",
"    ]. It is also unknown why pseudoporphyria usually continues for months after the drug has been discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1008808\">",
"    <span class=\"h2\">",
"     Hemodialysis and peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudoporphyria occurs in patients with chronic renal failure who are receiving chronic hemodialysis or peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. In case series, 1 to 16 percent of patients on hemodialysis developed the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=see_link\">",
"     Aluminum hydroxide",
"    </a>",
"    in dialysis solutions or chemicals in polyvinyl chloride dialysis tubing are suspected to be the photosensitizing agents in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Other theories include an inability to handle oxidative stress due to reduced levels of the endogenous antioxidant glutathione [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21925405\">",
"    <span class=\"h2\">",
"     Tanning beds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudoporphyria was reported in a small number of women with frequent exposure to high doses of UVA radiation from tanning beds [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. In some cases, the patients were using medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , antibiotics, or oral contraceptives) that are known inducers of pseudoporphyria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30223506\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic features of pseudoporphyria closely resemble those of porphyria. Histologic examination of a bullous lesion typically shows a noninflammatory subepidermal blister with a scant perivascular lymphocytic infiltrate. Festooning (ie, the preservation of the dermal papillae in the floor of the lesion) may be seen (",
"    <a class=\"graphic graphic_picture graphicRef83260 \" href=\"UTD.htm?19/34/20007\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/1,35,45,50\">",
"     1,35,45,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytoid or &ldquo;caterpillar&rdquo; bodies, which are considered a specific histopathologic finding of porphyrias, are also seen in pseudoporphyria (",
"    <a class=\"graphic graphic_picture graphicRef83388 \" href=\"UTD.htm?35/52/36678\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Caterpillar bodies are segmented and elongated structures containing laminin and type IV collagen that are positioned parallel to the epidermis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endothelial wall thickening from periodic acid-Schiff-positive, diastase-resistant material may be seen in the upper dermal microvasculature.",
"   </p>",
"   <p>",
"    Direct immunofluorescence of lesional and perilesional skin reveals changes similar to those seen in porphyria cutanea tarda (PCT). IgG, IgM, C3, and fibrinogen are frequently found at the dermoepidermal junction and in the vessel walls of lesional and perilesional skin (",
"    <a class=\"graphic graphic_picture graphicRef83261 \" href=\"UTD.htm?32/0/32775\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/50\">",
"     50",
"    </a>",
"    ]. Deposits of immunoglobulin and complement may be seen in the dermal vasculature in a doughnut-shaped pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/50,53\">",
"     50,53",
"    </a>",
"    ]. However, the absence of immunoreactants in dermal vessels and at the basement membrane zone does not exclude the diagnosis of pseudoporphyria.",
"   </p>",
"   <p>",
"    Immunofluorescent antigen mapping has been performed to determine the level of skin splitting in pseudoporphyria. Using this technique, type IV collagen, laminin, and bullous pemphigoid antigen have been observed at the base of the blister, with no characteristic cleavage level [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/54\">",
"     54",
"    </a>",
"    ]. However, ultrastructural studies have shown a split in the superficial dermis, with the basal lamina, hemidesmosomes, anchoring fibrils, and collagen fibers in the roof of the blister [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/21,45\">",
"     21,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30223513\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pseudoporphyria present with bullae and vesicles typically localized to the dorsum of the hands, forearms, and face (",
"    <a class=\"graphic graphic_picture graphicRef80856 graphicRef83262 graphicRef83391 \" href=\"UTD.htm?8/24/8586\">",
"     picture 4A-C",
"    </a>",
"    ). Lesions may also occur on the lower legs and feet. Skin fragility and easy bruising after minor trauma are common complaints. (",
"    <a class=\"graphic graphic_picture graphicRef83391 \" href=\"UTD.htm?27/29/28113\">",
"     picture 4C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/18,19,55\">",
"     18,19,55",
"    </a>",
"    ]. Bullae heal with scarring and milia in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/3,15,21,53,56\">",
"     3,15,21,53,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast with porphyria cutanea tarda, hypertrichosis, hyperpigmentation, and sclerodermoid changes are rarely reported in pseudoporphyria (",
"    <a class=\"graphic graphic_table graphicRef83258 \" href=\"UTD.htm?27/21/27995\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link&amp;anchor=H4527379#H4527379\">",
"     \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H298933\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, drug-induced pseudoporphyria has a protracted course. Cutaneous lesions continue to develop even after the offending drug has been discontinued. In one series of 16 patients, the symptoms resolved within 6 months of discontinuation of the medication in 5 patients, but persisted for an average of 2.5 years after discontinuation in 11 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30223520\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pseudoporphyria is based upon the combination of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous manifestations similar to those found in porphyria cutanea tarda (PCT), eg, skin fragility, vesicles and bullae involving sun exposed skin, particularly the face and the dorsum of the hands (",
"      <a class=\"graphic graphic_picture graphicRef80856 graphicRef83262 \" href=\"UTD.htm?28/3/28728\">",
"       picture 4A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Histologic finding of subepidermal blister with scant perivascular lymphocytic infiltrate (",
"      <a class=\"graphic graphic_picture graphicRef83260 \" href=\"UTD.htm?19/34/20007\">",
"       picture 1",
"      </a>",
"      ). On direct immunofluorescence, detection of IgG, IgM, C3, and fibrinogen at the dermal-epidermal junction and in the vessel walls (",
"      <a class=\"graphic graphic_picture graphicRef83261 \" href=\"UTD.htm?32/0/32775\">",
"       picture 3",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      Normal porphyrin levels in plasma, urine, and stool. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link&amp;anchor=H4527425#H4527425\">",
"       \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Laboratory findings'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reported use of potentially phototoxic medications (",
"      <a class=\"graphic graphic_table graphicRef83233 \" href=\"UTD.htm?14/36/14924\">",
"       table 2",
"      </a>",
"      ), history of chronic renal failure and dialysis, or UVA exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical and histologic features of pseudoporphyria closely resemble those of porphyria cutanea tarda. Pseudoporphyria often is only considered after evaluation for PCT has revealed normal porphyrin levels, which are the essential diagnostic criterion of pseudoporphyria.",
"   </p>",
"   <p>",
"    In some instances, it may be necessary to obtain serology for antinuclear antibodies, antitype VII collagen antibodies, and",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibodies to exclude bullous lupus or epidermolysis bullosa acquisita. (See",
"    <a class=\"local\" href=\"#H30223527\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Phototesting is not helpful in the evaluation of patients suspected of having pseudoporphyria. Although some individuals will exhibit a reduced minimal erythema dose (MED) to UVA, neither phototesting nor photoprovocation testing has been successful in reproducing the subepidermal blisters characteristic of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30223527\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudoporphyria should be differentiated from other bullous disorders presenting with similar clinical manifestations and normal porphyrin metabolism, including:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8050207\">",
"    <span class=\"h2\">",
"     Epidermolysis bullosa acquisita",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermolysis bullosa acquisita is a rare autoimmune bullous disease caused by autoantibodies against type VII collagen (",
"    <a class=\"graphic graphic_picture graphicRef62505 graphicRef83259 \" href=\"UTD.htm?32/1/32793\">",
"     picture 5A-B",
"    </a>",
"    ). Serous or hemorrhagic blisters are localized to areas of trauma, especially on the dorsum of the hands and feet and elbows. They heal with scarring, milia, and hyperpigmentation. On direct immunofluorescence, there is a linear deposit of IgG at the basement membrane zone. Circulating autoantibodies against collagen VII can be demonstrated by ELISA techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=see_link\">",
"     \"Epidermolysis bullosa acquisita\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8050214\">",
"    <span class=\"h2\">",
"     Bullous pemphigoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bullous pemphigoid is an autoimmune bullous disease occurring most commonly in older individuals. Urticarial plaques and tense bullae may occur in all body areas (",
"    <a class=\"graphic graphic_picture graphicRef79112 \" href=\"UTD.htm?30/33/31251\">",
"     picture 6",
"    </a>",
"    ). Direct immunofluorescence of perilesional skin shows IgG and C3, or C3 alone along the basement-membrane zone. Circulating antibodies against the bullous pemphigoid antigen BP 180 can be detected by ELISA techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8050230\">",
"    <span class=\"h2\">",
"     Bullous lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bullous lupus erythematosus is an uncommon form of systemic lupus erythematosus caused by autoantibodies against type VII collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/57\">",
"     57",
"    </a>",
"    ]. Vesicles and tense bullae are most often localized to the neck and upper trunk, but also may develop on unexposed skin (",
"    <a class=\"graphic graphic_picture graphicRef66048 \" href=\"UTD.htm?9/18/9504\">",
"     picture 7",
"    </a>",
"    ). Direct immunofluorescence demonstrates linear deposition of IgG, IgA, IgM, and C3 along the dermoepidermal junction. Salt-split skin is positive for IgG, IgA, and IgM on the floor of the blister. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link&amp;anchor=H10#H10\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Bullous skin lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8050245\">",
"    <span class=\"h2\">",
"     Hydroa vacciniforme",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with facial blistering, hydroa vacciniforme (",
"    <a class=\"graphic graphic_picture graphicRef68305 graphicRef54500 \" href=\"UTD.htm?13/45/14040\">",
"     picture 8A-B",
"    </a>",
"    ) can mimic pseudoporphyria. Hydroa vacciniforme is a rare photodermatosis of childhood characterized by vesicular lesions on sun-exposed skin that heal leaving depressed scars. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link&amp;anchor=H10#H10\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\", section on 'Hydroa vacciniforme'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30223534\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with drug-induced pseudoporphyria, discontinuation of the offending agent (if possible) is a crucial aspect of management. The resolution of the clinical manifestations is slow. Patients can expect gradual improvement with a decrease in blistering and skin fragility over a period of months to years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Photoprotection is essential for [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/20,58\">",
"       20,58",
"      </a>",
"      ] all patients with pseudoporphyria. Photoprotection should continue at least until resolution of symptoms. Photoprotection measures include sun avoidance, use of protective clothing (long-sleeved shirts, blouses, pants, wide-brimmed hats), and broad-spectrum sunscreens (",
"      <a class=\"graphic graphic_table graphicRef58215 \" href=\"UTD.htm?8/51/9019\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27142?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection\", section on 'Photoprotection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A beneficial effect of N-acetylcysteine has been reported in a few patients with chronic renal failure and hemodialysis-associated pseudoporphyria [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21111/abstract/59-64\">",
"       59-64",
"      </a>",
"      ]. N-acetylcysteine is a precursor of glutathione, an endogenous antioxidant, the levels of which are reduced in hemodialysis patients. For patients with pseudoporphyria associated with excessive exposure to artificial UVA sources from tanning beds, discontinuation of the practice is essential for the control of disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H656218\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudoporphyria is a bullous photodermatosis with the clinical and histologic features of porphyria cutanea tarda (PCT), in the absence of abnormalities in porphyrin metabolism. Pseudoporphyria has been reported in approximately 10 percent of children taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      for juvenile idiopathic arthritis. (See",
"      <a class=\"local\" href=\"#H30223457\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30223464\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the exact pathogenetic mechanism is unknown, pseudoporphyria is considered a photodynamic phototoxic drug reaction. It is most often caused by medications, including nonsteroidal antiinflammatory drugs (NSAIDs), antibiotics, diuretics, and antineoplastic agents (",
"      <a class=\"graphic graphic_table graphicRef83233 \" href=\"UTD.htm?14/36/14924\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30223471\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of pseudoporphyria closely resemble those of PCT and include skin fragility, bullae and vesicles involving sun-exposed areas of the body, such as the face and dorsum of the hands (",
"      <a class=\"graphic graphic_picture graphicRef80856 graphicRef83262 \" href=\"UTD.htm?28/3/28728\">",
"       picture 4A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30223513\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of pseudoporphyria is made in a patient with clinical and histologic features of PCT; normal porphyrin levels in red blood cells, plasma, urine, and stool; and reported use of phototoxic medications, hemodialysis, or tanning beds. (See",
"      <a class=\"local\" href=\"#H30223520\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudoporphyria should be differentiated from bullous disorders presenting with similar clinical manifestations, including epidermolysis bullosa acquisita (",
"      <a class=\"graphic graphic_picture graphicRef62505 graphicRef83259 \" href=\"UTD.htm?32/1/32793\">",
"       picture 5A-B",
"      </a>",
"      ), bullous pemphigoid (",
"      <a class=\"graphic graphic_picture graphicRef79112 \" href=\"UTD.htm?30/33/31251\">",
"       picture 6",
"      </a>",
"      ), pemphigus (",
"      <a class=\"graphic graphic_picture graphicRef53425 \" href=\"UTD.htm?26/56/27526\">",
"       picture 9",
"      </a>",
"      ), bullous lupus erythematosus (",
"      <a class=\"graphic graphic_picture graphicRef66048 \" href=\"UTD.htm?9/18/9504\">",
"       picture 7",
"      </a>",
"      ), and hydroa vacciniforme (",
"      <a class=\"graphic graphic_picture graphicRef68305 graphicRef54500 \" href=\"UTD.htm?13/45/14040\">",
"       picture 8A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30223527\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discontinuation of the offending agent and photoprotection are the most important aspects of the management of patients with pseudoporphyria. (See",
"      <a class=\"local\" href=\"#H30223534\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27142?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection\", section on 'Photoprotection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/1\">",
"      Green JJ, Manders SM. Pseudoporphyria. J Am Acad Dermatol 2001; 44:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/2\">",
"      De Silva B, Banney L, Uttley W, et al. Pseudoporphyria and nonsteroidal antiinflammatory agents in children with juvenile idiopathic arthritis. Pediatr Dermatol 2000; 17:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/3\">",
"      Levy ML, Barron KS, Eichenfield A, Honig PJ. Naproxen-induced pseudoporphyria: a distinctive photodermatitis. J Pediatr 1990; 117:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/4\">",
"      Sch&auml;d SG, Kraus A, Haubitz I, et al. Early onset pauciarticular arthritis is the major risk factor for naproxen-induced pseudoporphyria in juvenile idiopathic arthritis. Arthritis Res Ther 2007; 9:R10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/5\">",
"      ZELICKSON AS. PHOTOTOXIC REACTION WITH NALIDIXIC ACID. JAMA 1964; 190:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/6\">",
"      Ramsay CA. Photosensitivity from nalidixic acid. Proc R Soc Med 1973; 66:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/7\">",
"      Ramsay CA, Obreshkova E. Photosensitivity from nalidixic acid. Br J Dermatol 1974; 91:523.",
"     </a>",
"    </li>",
"    <li>",
"     Frank J, Poblete-Gutierrez R. Porphyria. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP, et al (Eds), Mosby Elsevier, 2008. p.648.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/9\">",
"      Sharp MT, Horn TD. Pseudoporphyria induced by voriconazole. J Am Acad Dermatol 2005; 53:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/10\">",
"      Kwong WT, Hsu S. Pseudoporphyria associated with voriconazole. J Drugs Dermatol 2007; 6:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/11\">",
"      Tolland JP, McKeown PP, Corbett JR. Voriconazole-induced pseudoporphyria. Photodermatol Photoimmunol Photomed 2007; 23:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/12\">",
"      Dolan CK, Hall MA, Blazes DL, Norwood CW. Pseudoporphyria as a result of voriconazole use: a case report. Int J Dermatol 2004; 43:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/13\">",
"      Berghoff AT, English JC 3rd. Imatinib mesylate-induced pseudoporphyria. J Am Acad Dermatol 2010; 63:e14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/14\">",
"      Timmer-de Mik L, Kardaun SH, Kramer MH, et al. Imatinib-induced pseudoporphyria. Clin Exp Dermatol 2009; 34:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/15\">",
"      Lang BA, Finlayson LA. Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis. J Pediatr 1994; 124:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/16\">",
"      Girschick HJ, Hamm H, Ganser G, Huppertz HI. Naproxen-induced pseudoporphyria: appearance of new skin lesions after discontinuation of treatment. Scand J Rheumatol 1995; 24:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/17\">",
"      Creemers MC, Chang A, Franssen MJ, et al. Pseudoporphyria due to naproxen. A cluster of 3 cases. Scand J Rheumatol 1995; 24:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/18\">",
"      Burns DA. Naproxen pseudoporphyria in a patient with vitiligo. Clin Exp Dermatol 1987; 12:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/19\">",
"      Diffey BL, Farr PM. Naproxen pseudoporphyria in a patient with vitiligo. Clin Exp Dermatol 1988; 13:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/20\">",
"      Rivers JK, Barnetson RS. Naproxen-induced bullous photodermatitis. Med J Aust 1989; 151:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/21\">",
"      Judd LE, Henderson DW, Hill DC. Naproxen-induced pseudoporphyria. A clinical and ultrastructural study. Arch Dermatol 1986; 122:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/22\">",
"      Suarez SM, Cohen PR, DeLeo VA. Bullous photosensitivity to naproxen: \"pseudoporphyria\". Arthritis Rheum 1990; 33:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/23\">",
"      Taylor BJ, Duffill MB. Pseudoporphyria from nonsteroidal antiinflammatory drugs. N Z Med J 1987; 100:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/24\">",
"      Cummins R, Wagner-Weiner L, Paller A. Pseudoporphyria induced by celecoxib in a patient with juvenile rheumatoid arthritis. J Rheumatol 2000; 27:2938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/25\">",
"      LaDuca JR, Bouman PH, Gaspari AA. Nonsteroidal antiinflammatory drug-induced pseudoporphyria: a case series. J Cutan Med Surg 2002; 6:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/26\">",
"      Cron RQ, Finkel TH. Nabumetone induced pseudoporphyria in childhood. J Rheumatol 2000; 27:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/27\">",
"      Checketts SR, Morgan GJ Jr. Two cases of nabumetone induced pseudoporphyria. J Rheumatol 1999; 26:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/28\">",
"      Meggitt SJ, Farr PM. Pseudoporphyria and propionic acid non-steroidal anti-inflammatory drugs. Br J Dermatol 1999; 141:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/29\">",
"      Magro CM, Crowson AN. Pseudoporphyria associated with Relafen therapy. J Cutan Pathol 1999; 26:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/30\">",
"      Krischer J, Scolari F, Kondo-Oestreicher M, et al. Pseudoporphyria induced by nabumetone. J Am Acad Dermatol 1999; 40:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/31\">",
"      Varma S, Lanigan SW. Pseudoporphyria caused by nabumetone. Br J Dermatol 1998; 138:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/32\">",
"      Al-Khenaizan S, Schechter JF, Sasseville D. Pseudoporphyria induced by propionic acid derivatives. J Cutan Med Surg 1999; 3:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/33\">",
"      Antony F, Layton AM. Nabumetone-associated pseudoporphyria. Br J Dermatol 2000; 142:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/34\">",
"      O'Hagan AH, Irvine AD, Allen GE, Walsh M. Pseudoporphyria induced by mefenamic acid. Br J Dermatol 1998; 139:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/35\">",
"      Epstein JH, Seibert JS. Porphyria-like cutaneous changes induced by tetracycline hydrochloride photosensitization. Arch Dermatol 1976; 112:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/36\">",
"      Gilchrest B, Rowe JW, Mihm MC Jr. Bullous dermatosis of hemodialysis. Ann Intern Med 1975; 83:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/37\">",
"      Harvey E, Bell CH, Paller AS, et al. Pseudoporphyria cutanea tarda: two case reports on children receiving peritoneal dialysis and erythropoietin therapy. J Pediatr 1992; 121:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/38\">",
"      Glynne P, Deacon A, Goldsmith D, et al. Bullous dermatoses in end-stage renal failure: porphyria or pseudoporphyria? Am J Kidney Dis 1999; 34:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/39\">",
"      Brivet F, Dr&uuml;eke T, Guillemette J, et al. Porphyria cutanea tarda-like syndrome in hemodialyzed patients. Nephron 1978; 20:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/40\">",
"      Griffon-Euvrard S, Thivolet J, Laurent G, et al. [Detection of pseudo-porphyria cutanea tarda in 100 hemodialyzed patients (author's transl)]. Dermatologica 1977; 155:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/41\">",
"      Attia EA, Hassan SI, Youssef NM. Cutaneous disorders in uremic patients on hemodialysis: an Egyptian case-controlled study. Int J Dermatol 2010; 49:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/42\">",
"      Bencini PL, Montagnino G, Citterio A, et al. Cutaneous abnormalities in uremic patients. Nephron 1985; 40:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/43\">",
"      Neergaard J, Nielsen B, Faurby V, et al. On the exudation of plasticizers from PVC haemodialysis tubings. Nephron 1975; 14:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/44\">",
"      Schettler V, Wieland E, Methe H, et al. Oxidative stress during dialysis: effect on free radical scavenging enzyme (FRSE) activities and glutathione (GSH) concentration in granulocytes. Nephrol Dial Transplant 1998; 13:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/45\">",
"      Murphy GM, Wright J, Nicholls DS, et al. Sunbed-induced pseudoporphyria. Br J Dermatol 1989; 120:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/46\">",
"      Wilson CL, Mendelsohn SS. Identical twins with sunbed-induced pseudoporphyria. J R Soc Med 1992; 85:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/47\">",
"      Stenberg A. Pseudoporphyria and sunbeds. Acta Derm Venereol 1990; 70:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/48\">",
"      Thomsen K. Solarium pseudoporphyria. Photodermatol 1989; 6:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/49\">",
"      Kochs C, M&uuml;hlenst&auml;dt E, Neumann NJ, Hanneken S. [Solarium-induced pseudoporphyria and variegate porphyria as rare differential diagnoses of porphyria cutanea tarda]. Hautarzt 2009; 60:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/50\">",
"      Maynard B, Peters MS. Histologic and immunofluorescence study of cutaneous porphyrias. J Cutan Pathol 1992; 19:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/51\">",
"      Fung MA, Murphy MJ, Hoss DM, et al. The sensitivity and specificity of \"caterpillar bodies\" in the differential diagnosis of subepidermal blistering disorders. Am J Dermatopathol 2003; 25:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/52\">",
"      Egbert BM, LeBoit PE, McCalmont T, et al. Caterpillar bodies: distinctive, basement membrane-containing structures in blisters of porphyria. Am J Dermatopathol 1993; 15:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/53\">",
"      Schanbacher CF, Vanness ER, Daoud MS, et al. Pseudoporphyria: a clinical and biochemical study of 20 patients. Mayo Clin Proc 2001; 76:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/54\">",
"      Dabski C, Beutner EH. Studies of laminin and type IV collagen in blisters of porphyria cutanea tarda and drug-induced pseudoporphyria. J Am Acad Dermatol 1991; 25:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/55\">",
"      Motley RJ. Pseudoporphyria due to dyazide in a patient with vitiligo. BMJ 1990; 300:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/56\">",
"      Wallace CA, Farrow D, Sherry DD. Increased risk of facial scars in children taking nonsteroidal antiinflammatory drugs. J Pediatr 1994; 125:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/57\">",
"      Sebaratnam DF, Murrell DF. Bullous systemic lupus erythematosus. Dermatol Clin 2011; 29:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/58\">",
"      Burry JN, Lawrence JR. Phototoxic blisters from high frusemide dosage. Br J Dermatol 1976; 94:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/59\">",
"      Massone C, Ambros-Rudolph CM, Di Stefani A, M&uuml;llegger RR. Successful outcome of haemodialysis-induced pseudoporphyria after short-term oral N-acetylcysteine and switch to high-flux technique dialysis. Acta Derm Venereol 2006; 86:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/60\">",
"      Tremblay JF, Veilleux B. Pseudoporphyria associated with hemodialysis treated with N-acetylcysteine. J Am Acad Dermatol 2003; 49:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/61\">",
"      Vadoud-Seyedi J, de Dobbeleer G, Simonart T. Treatment of haemodialysis-associated pseudoporphyria with N-acetylcysteine: report of two cases. Br J Dermatol 2000; 142:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/62\">",
"      Cooke NS, McKenna K. A case of haemodialysis-associated pseudoporphyria successfully treated with oral N-acetylcysteine. Clin Exp Dermatol 2007; 32:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/63\">",
"      Kasuya A, Hashizume H, Hirakawa S, Tokura Y. Haemodialysis-induced pseudoporphyria successfully treated with glutathione. Eur J Dermatol 2012; 22:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21111/abstract/64\">",
"      Guiotoku MM, Pereira Fde P, Miot HA, Marques ME. Pseudoporphyria induced by dialysis treated with oral N-acetylcysteine. An Bras Dermatol 2011; 86:383.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13748 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21111=[""].join("\n");
var outline_f20_39_21111=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H656218\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30223457\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30223464\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30223471\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182198836\">",
"      UV radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21925384\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1008808\">",
"      Hemodialysis and peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21925405\">",
"      Tanning beds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30223506\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30223513\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H298933\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30223520\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30223527\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8050207\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8050214\">",
"      Bullous pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8050230\">",
"      Bullous lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8050245\">",
"      Hydroa vacciniforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30223534\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H656218\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13748\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13748|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/34/20007\" title=\"picture 1\">",
"      Pseudoporphyria histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/52/36678\" title=\"picture 2\">",
"      Caterpillar bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/0/32775\" title=\"picture 3\">",
"      Pseudoporphyria immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/42/19109\" title=\"picture 4A\">",
"      Pseudoporphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/58/30625\" title=\"picture 4B\">",
"      Pseudoporphyria 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/29/28113\" title=\"picture 4C\">",
"      Pseudoporphyria and vitiligo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/36/22085\" title=\"picture 5A\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/40/11909\" title=\"picture 5B\">",
"      Epidermolysis bullosa acquisita hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/33/31251\" title=\"picture 6\">",
"      Bullous pemphigoid on urticarial plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/18/9504\" title=\"picture 7\">",
"      Bullous lupus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/14/23779\" title=\"picture 8A\">",
"      Hydroa vacciniforme 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/39/40562\" title=\"picture 8B\">",
"      Hydroa vacciniforme 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/56/27526\" title=\"picture 9\">",
"      Pemphigus vulgaris bullae and erosions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13748|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/37/15963\" title=\"table 1\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/36/14924\" title=\"table 2\">",
"      Drugs inducing pseudoporphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/21/27995\" title=\"table 3\">",
"      Pseudoporphyria and PCT differential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/51/9019\" title=\"table 4\">",
"      Broad spectrum sunscreens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5801?source=related_link\">",
"      Congenital erythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=related_link\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27142?source=related_link\">",
"      Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=related_link\">",
"      Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=related_link\">",
"      Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/51/825?source=related_link\">",
"      Variegate porphyria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_39_21112="Weaning from mechanical ventilation: Readiness testing";
var content_f20_39_21112=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Weaning from mechanical ventilation: Readiness testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/39/21112/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/39/21112/contributors\">",
"     Scott K Epstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/39/21112/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/39/21112/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/39/21112/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/39/21112/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/39/21112/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuing mechanical ventilation is a two-step process:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Readiness testing &ndash; During readiness testing, objective clinical criteria are evaluated to determine whether a patient is ready to begin weaning. Some clinicians also consider physiological tests, known as weaning predictors, because they are hesitant to begin weaning on the basis of clinical criteria alone. The clinical criteria and weaning predictors are defined and described below.",
"     </li>",
"     <li>",
"      Weaning &ndash; Weaning is the process of decreasing ventilator support and allowing patients to assume a greater proportion of their ventilation. It may involve either an immediate shift from full ventilatory support to a period of breathing without assistance from the ventilator (ie, a spontaneous breathing trial [SBT]) or a gradual reduction in the amount of ventilator support [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. Regardless of which approach is chosen, extubation is considered once the patient demonstrates the ability to breathe without the ventilator and both airway patency and airway protection have been assessed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=see_link\">",
"       \"Extubation management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Readiness testing is reviewed here. Weaning and extubation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14423?source=see_link\">",
"     \"Methods of weaning from mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=see_link\">",
"     \"Extubation management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PURPOSE OF READINESS TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Readiness testing has two major purposes. The first is to identify patients who are ready to wean from mechanical ventilation. This is important because clinicians tend to underestimate the capacity of patients to breathe independently. Unnecessary mechanical ventilation needlessly increases the risk of complications related to mechanical ventilation.",
"   </p>",
"   <p>",
"    Potential complications of mechanical ventilation include pulmonary barotrauma, ventilator-associated lung injury, ventilator-associated pneumonia, sinusitis, airway injury, venous thromboembolism, and gastrointestinal bleeding. In addition, mortality is associated with both prolonged weaning and the duration of mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. While this association may simply be a marker of the severity of illness, the complications associated with mechanical ventilation may also contribute. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=see_link\">",
"     \"Physiologic and pathophysiologic consequences of mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=see_link\">",
"     \"Ventilator-associated lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=see_link\">",
"     \"Pulmonary barotrauma during mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The tendency of clinicians to underestimate the capacity of patients to breathe independently from the ventilator was initially suggested by two randomized trials that found that 65 to 85 percent of the patients tolerated discontinuation of mechanical ventilation on the same day that their readiness to wean was first assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This was supported by a subsequent case-control study that found that 50 percent of patients who self-extubated never required reintubation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The second major purpose of readiness testing is to identify patients who are not ready for weaning, thereby protecting them against the risks of premature weaning (eg, cardiovascular dysfunction, respiratory muscle fatigue, psychological distress).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consensus conference composed of clinicians with expertise in discontinuing mechanical ventilation proposed several clinical criteria that can be used to identify patients who are ready to begin weaning (",
"    <a class=\"graphic graphic_table graphicRef62377 \" href=\"UTD.htm?36/34/37419\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/6\">",
"     6",
"    </a>",
"    ]. All of the criteria are objective, since clinicians are poor at predicting readiness to wean on the basis of their subjective impression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However, even objective criteria are imperfect, since up to 30 percent of patients who never satisfy such criteria can be successfully weaned [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The criteria can be segregated into required and optional criteria. All of the criteria derive from observational studies that found that they predicted safe weaning, as well as from the experience of the clinicians who attended the consensus conference. None of the criteria have been validated in randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Required criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are required criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cause of the respiratory failure has improved.",
"     </li>",
"     <li>",
"      Adequate oxygenation &ndash; This may be indicated by either a ratio of arterial oxygen tension to fraction of inspired oxygen",
"      <span class=\"nowrap\">",
"       (PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"       )",
"      </span>",
"      &ge;150 mmHg or an oxyhemoglobin saturation (SpO",
"      <sub>",
"       2",
"      </sub>",
"      ) &ge;90 percent while receiving an FiO",
"      <sub>",
"       2",
"      </sub>",
"      &le;40 percent and a positive end-expiratory pressure (PEEP) &le;5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O. For patients who have chronic hypoxemia, a",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &ge;120 mmHg may be used instead. These thresholds are empiric, since no study has established a minimal acceptable PaO",
"      <sub>",
"       2",
"      </sub>",
"      ,",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"       ,",
"      </span>",
"      SpO",
"      <sub>",
"       2",
"      </sub>",
"      , or alveolar-arterial oxygen gradient for weaning.",
"     </li>",
"     <li>",
"      Arterial pH &gt;7.25",
"     </li>",
"     <li>",
"      Hemodynamic stability, without myocardial ischemia &ndash; The blood pressure thresholds below or above which it is unsafe for a patient to wean have not been established. However, it seems reasonable to require that the systolic blood pressure be &gt;90 mmHg or &lt;180 mmHg to begin weaning. The use of vasopressors to maintain the systolic blood pressure &gt;90 mmHg is acceptable, but only low doses should be necessary (eg, dopamine &lt;5",
"      <span class=\"nowrap\">",
"       mcg/kg/min).",
"      </span>",
"     </li>",
"     <li>",
"      The patient is able to initiate an inspiratory effort.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Optional criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast, the following criteria are optional [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemoglobin level &ge;7 to 10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      &ndash; Previously, any degree of anemia was considered a contraindication to weaning because it reduces oxygen carrying capacity. However, only severe anemia is currently considered a contraindication to weaning. The change is largely due to a secondary analysis of a randomized trial that compared a restrictive blood transfusion strategy (ie, maintain hemoglobin level of 7 to 10",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      to a liberal strategy (ie, maintain a hemoglobin level of 10 to 12",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/9\">",
"       9",
"      </a>",
"      ]. The analysis found that the strategies had no effect on the rate of successful weaning (78 versus 82 percent).",
"     </li>",
"     <li>",
"      Core temperature &le;38 to 38.5&ordm;C &ndash; The rationale for this criterion is that the presence of fever makes successful weaning less likely because it increases the minute ventilation and, thus, the load on the respiratory system. It is also associated with rapid breathing. Patients whose fever is caused by sepsis may also have diminished respiratory muscle function [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/10\">",
"       10",
"      </a>",
"      ]. A temperature threshold above which weaning is unsafe has not been identified.",
"     </li>",
"     <li>",
"      A mental status that is either awake and alert, or easily arousable &ndash; This criterion is considered optional because although an awake or easily arousable patient is ideal for weaning, an abnormal mental status (ie, Glasgow Coma Scale score &lt;8 or the inability to follow simple commands) does not appear to be associated with a higher rate of extubation failure [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Thus, as long as a patient can protect the airway, an abnormal mental status does not preclude extubation. Evaluation of the ability to protect the airway is described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=see_link&amp;anchor=H3#H3\">",
"       \"Extubation management\", section on 'Airway protection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of these objective clinical criteria alone to assess a patient's readiness to wean (without the aid of a weaning predictor) is described below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Approach to readiness testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     WEANING PREDICTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians are hesitant to begin weaning on the basis of clinical criteria alone. Thus, they also use physiological tests to predict whether a patient is likely to tolerate weaning (",
"    <a class=\"graphic graphic_table graphicRef78201 \" href=\"UTD.htm?43/0/44044\">",
"     table 2",
"    </a>",
"    ). These physiological tests are called weaning predictors.",
"   </p>",
"   <p>",
"    Weaning predictor measurements should identify all patients ready to breathe independently and they should be safe and easy to perform, highly reproducible, and not subject to confounding influences. They should also use equipment and techniques that are routinely available in intensive care units. Measurements that require special equipment or invasive techniques are unlikely to find widespread use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rapid shallow breathing index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapid shallow breathing index (RSBI) is the ratio of respiratory frequency to tidal volume",
"    <span class=\"nowrap\">",
"     (f/VT).",
"    </span>",
"    It is the most extensively studied and commonly used weaning predictor. Its definition, accuracy, effect on clinical outcomes, and measurement are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21140?source=see_link\">",
"     \"Weaning from mechanical ventilation: The rapid shallow breathing index\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Oxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although adequate oxygenation is an essential clinical criterion to consider when deciding whether a patient is ready to wean (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical criteria'",
"    </a>",
"    above), it is a poor weaning predictor when used alone to predict weaning outcome. This was illustrated by two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial investigating the impact of daily awakening trials, spontaneous breathing trials (SBTs) were safe and often successful even among patients with relatively poor oxygenation (eg, a",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      of only 110 to 120) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective cohort study of 269 patients found that a ratio of arterial oxygen tension to fraction of inspired oxygen",
"      <span class=\"nowrap\">",
"       (PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"       )",
"      </span>",
"      &ge;238 mmHg predicted weaning success with a negative predictive value of only 10 percent (the positive predictive value was 90 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/14\">",
"       14",
"      </a>",
"      ]. These results should be interpreted with caution because the positive predictive value may be higher and the negative predictive value may be lower than in most populations, since the pretest probability of weaning success was unusually high (90 percent) in the study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reason that indices of oxygenation are poor weaning predictors is probably test referral bias, which exists when the test being studied is used to select patients for a reference standard test. In this case, most of the studies required adequate oxygenation (the test being studied) in order to begin weaning (the reference standard). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=see_link\">",
"     \"Evaluating diagnostic tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Minute ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total minute ventilation estimates the demand on the respiratory system. It is approximately 5 to 6",
"    <span class=\"nowrap\">",
"     liters/min",
"    </span>",
"    in healthy individuals at rest, but increases among patients who are mechanically ventilated or have increased carbon dioxide production (eg, fever, hypermetabolic states), metabolic acidosis, hypoxemia, increased dead space,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an increased central respiratory drive.",
"   </p>",
"   <p>",
"    Since elevated total minute ventilation is indicative of increased respiratory demand, it is reasonable to expect that elevated total minute ventilation might predict weaning failure. However, a systematic review found that minute ventilation is a poor predictor of weaning outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/15\">",
"     15",
"    </a>",
"    ]. The positive and negative predictive values were low and the likelihood ratio positive (LR+) ranged from 0.87 to 2.37, indicating that there is little or no increase in the probability of weaning among patients whose minute ventilation does not exceed a particular threshold (usually &gt;10 to 15",
"    <span class=\"nowrap\">",
"     liters/min).",
"    </span>",
"    Likelihood ratios are described in the table (",
"    <a class=\"graphic graphic_table graphicRef72793 \" href=\"UTD.htm?5/40/5771\">",
"     table 3",
"    </a>",
"    ) and separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21140?source=see_link&amp;anchor=H3#H3\">",
"     \"Weaning from mechanical ventilation: The rapid shallow breathing index\", section on 'Accuracy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Maximal inspiratory pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maximal inspiratory pressure (MIP or PImax) is a global assessment of the strength of the inspiratory muscles. It can be measured by attaching an aneroid manometer to the opening of the endotracheal tube and asking the patient to maximally inspire against an occluded airway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=see_link\">",
"     \"Tests of respiratory muscle strength\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial studies suggested that a MIP of -30 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O or less (ie, more negative) was associated with successful weaning, while a MIP of -20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O or more (ie less negative) was associated with weaning failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/16\">",
"     16",
"    </a>",
"    ]. However, a subsequent systematic review of more than 30 studies found that the MIP is a poor predictor of weaning outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The systematic review found that an adequate MIP predicts weaning success with a low sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, the pooled LR+ ranged from 1.15 to 1.57, while the pooled likelihood ratio negative (LR-) ranged from 0.31 to 0.65. These results indicate that there is little or no increase in the probability of weaning success among patients with a normal MIP, but a small increase in the probability of weaning failure among patients with a reduced MIP. Likelihood ratios are described in the table (",
"    <a class=\"graphic graphic_table graphicRef72793 \" href=\"UTD.htm?5/40/5771\">",
"     table 3",
"    </a>",
"    ) and separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21140?source=see_link&amp;anchor=H3#H3\">",
"     \"Weaning from mechanical ventilation: The rapid shallow breathing index\", section on 'Accuracy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One reason for the poor predictive capacity of the MIP may be its ability to assess only respiratory muscle strength and not the load placed on those muscles. In addition, accurate measurement of the MIP in a spontaneously breathing patient is challenging [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/17\">",
"     17",
"    </a>",
"    ]. The MIP tends to be underestimated because of insufficient patient effort. This can be improved by using a one-way valve that allows the patient to expire but not inspire. Keeping the valve occluded up to 20 to 25 seconds will move the patient to a maximal effort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Static respiratory system compliance (Cst,rs) is an indirect quantification of the work of breathing that is required to overcome the elastic forces of the respiratory system. It is estimated during a condition of zero gas flow:",
"   </p>",
"   <p>",
"    Cst,rs = VT",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    (plateau pressure - PEEP)",
"   </p>",
"   <p>",
"    where PEEP is the positive end-expiratory pressure. In a prospective cohort study, a decreased Cst,rs of 33",
"    <span class=\"nowrap\">",
"     mL/cm",
"    </span>",
"    H",
"    <sub>",
"     2",
"    </sub>",
"    O (normal 60 to 100",
"    <span class=\"nowrap\">",
"     mL/cm",
"    </span>",
"    H",
"    <sub>",
"     2",
"    </sub>",
"    O) had a poor predictive capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/18\">",
"     18",
"    </a>",
"    ]. The poor predictive capacity may be due to the inability of the Cst,rs to account for the capacity of the respiratory muscles to meet the increased load that the decreased compliance suggests is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Occlusion pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory drive can be estimated by measuring the airway pressure generated in the first 0.1 second (P0.1) during an inspiratory effort against an occluded airway. This technique required the use of special equipment to perform the airway occlusion in the past, but some currently available ventilators can measure the P0.1.",
"   </p>",
"   <p>",
"    The P0.1 is less than 2 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O in normal subjects. Patients who fail weaning have a higher P0.1 because they have an elevated respiratory drive. Values greater than 4 to 6 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O have been associated with weaning failure in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predictive accuracy of the P0.1 appears to increase significantly when the airway occlusion pressure is normalized for maximal inspiratory pressure",
"    <span class=\"nowrap\">",
"     (P0.1/MIP).",
"    </span>",
"    Higher values are associated with weaning failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Work of breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The work of breathing can be calculated from the tidal volume and the intrathoracic pressure that is generated by respiratory muscle contraction (measured using an esophageal balloon). It has been studied as a potential weaning predictor because it tends to be higher among patients who fail weaning compared to those who successfully wean [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. However, a precise value that discriminates patients who are likely to successfully wean from those who are likely to fail weaning has not been identified. The finding that the work of breathing may be helpful as a weaning predictor has not been universal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Gastric mucosal acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood flow may be diverted from the splanchnic vascular bed to the respiratory muscles during weaning in order to meet the oxygen demands of the respiratory muscles. This is most severe during weaning failure and may result in gastric mucosal acidosis (or gastric mucosal ischemia). Thus, gastric mucosal acidosis may be an indicator of weaning failure, although its utility is limited by the need for a special nasogastric tube.",
"   </p>",
"   <p>",
"    The concept was supported by several studies. A study of 29 mechanically ventilated patients found a lower gastric mucosal pH in patients who failed weaning compared to those successfully weaned [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/29\">",
"     29",
"    </a>",
"    ]. Another study of 19 mechanically ventilated patients found both a lower gastric mucosal pH and higher intraluminal gastric carbon dioxide (PgCO",
"    <sub>",
"     2",
"    </sub>",
"    ) among patients who failed weaning [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Oxygen cost of breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oxygen (O",
"    <sub>",
"     2",
"    </sub>",
"    ) cost of breathing is the difference between total O",
"    <sub>",
"     2",
"    </sub>",
"    consumption during spontaneous breathing and during relaxed mechanical ventilation. Its measurement requires special equipment (ie, a metabolic cart) that is not routinely available in most intensive care units.",
"   </p>",
"   <p>",
"    The O",
"    <sub>",
"     2",
"    </sub>",
"    cost of breathing is &lt;5 percent of the total O",
"    <sub>",
"     2",
"    </sub>",
"    consumption in most healthy subjects. It can exceed 50 percent in patients who are being weaned and tends to be highest among patients who are failing weaning; however, studies have failed to identify a threshold value that accurately discriminates patients who are at increased risk for weaning failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. An important limitation of the technique is that changes in nonrespiratory O",
"    <sub>",
"     2",
"    </sub>",
"    consumption can confound the measurement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Integrative indices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weaning failure usually results from a complex interplay of multiple factors. Thus, it is not surprising that predictors targeting a single pathophysiologic mechanism tend to be unreliable. Indices that integrate several physiologic mechanisms were developed in an attempt to further improve the accuracy of prediction. While several of the integrated indices look promising, none have been confirmed as having the high level of accuracy that was initially reported.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inspiratory effort quotient (IEQ) =",
"      <span class=\"nowrap\">",
"       [(0.75VT/Cdyn)",
"      </span>",
"      x",
"      <span class=\"nowrap\">",
"       (TI/TTOT)]",
"      </span>",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      MIP, where VT is the tidal volume, Cdyn is the dynamic compliance, TI is the inspiratory time, TTOT is the respiratory duty cycle, and MIP is the maximal inspiratory pressure. An IEQ &gt;0.15 has been suggested as the fatiguing threshold that predicts weaning failure [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The CROP index (",
"      <strong>",
"       C",
"      </strong>",
"      ompliance,",
"      <strong>",
"       R",
"      </strong>",
"      ate,",
"      <strong>",
"       O",
"      </strong>",
"      xygenation,",
"      <strong>",
"       P",
"      </strong>",
"      ressure) = [Cdyn * MIP *",
"      <span class=\"nowrap\">",
"       (PaO",
"       <sub>",
"        2",
"       </sub>",
"       /PAO",
"       <sub>",
"        2",
"       </sub>",
"       )]",
"      </span>",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      R, where Cdyn is the dynamic compliance, MIP is the maximal inspiratory pressure,",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /PAO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      is the ratio of arterial oxygen tension to alveolar oxygen, and R is the respiratory rate. A prospective cohort study found that a CROP of 13",
"      <span class=\"nowrap\">",
"       mL/breath/min",
"      </span>",
"      predicted weaning success with a positive and negative predictive value of 71 and 70 percent, respectively, in a population with a weaning success rate of approximately 60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/18\">",
"       18",
"      </a>",
"      ]. This was less accurate than the RSBI in the same study.",
"     </li>",
"     <li>",
"      The CORE index (",
"      <strong>",
"       C",
"      </strong>",
"      ompliance,",
"      <strong>",
"       O",
"      </strong>",
"      xygenation,",
"      <strong>",
"       R",
"      </strong>",
"      espiration,",
"      <strong>",
"       E",
"      </strong>",
"      ffort) = [Cdyn *",
"      <span class=\"nowrap\">",
"       (MIP/P",
"       <sub>",
"        0.1",
"       </sub>",
"       )",
"      </span>",
"      *",
"      <span class=\"nowrap\">",
"       (PaO",
"       <sub>",
"        2",
"       </sub>",
"       /PAO",
"       <sub>",
"        2",
"       </sub>",
"       )]",
"      </span>",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      R, where Cdyn is the dynamic compliance, MIP is the maximal inspiratory pressure, P",
"      <sub>",
"       0.1",
"      </sub>",
"      is the airway occlusion pressure 0.1 sec after the start of inspiratory flow,",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /PAO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      is the ratio of arterial oxygen tension to alveolar oxygen, and R is the respiratory rate. The CORE index was compared to both the CROP index and the RSBI in a study conducted with 47 mechanically ventilated patients who were recovering from respiratory failure due to various causes [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/35\">",
"       35",
"      </a>",
"      ]. The CORE index predicted weaning success with a likelihood ratio positive (LR+) of 20 and predicted weaning failure with a likelihood ratio negative (LR-) of 0.0. In contrast, the CROP index had an LR+ and LR- of 3.3 and 0.0, respectively, and the RSBI had an LR+ and LR- of 2.5 and 0.2, respectively. Likelihood ratios are described in the table (",
"      <a class=\"graphic graphic_table graphicRef72793 \" href=\"UTD.htm?5/40/5771\">",
"       table 3",
"      </a>",
"      ) and separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21140?source=see_link&amp;anchor=H3#H3\">",
"       \"Weaning from mechanical ventilation: The rapid shallow breathing index\", section on 'Accuracy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Weaning Index (WI) =",
"      <span class=\"nowrap\">",
"       PTI*(VE40/VTsb),",
"      </span>",
"      where PTI is the modified pressure time index, VE40 is the minute ventilation needed to bring PaCO",
"      <sub>",
"       2",
"      </sub>",
"      to 40 mmHg, and VTsb is the tidal volume during spontaneous breathing. The PTI is the time integral of respiratory muscle pressure and the VE40 is an estimate of the efficiency of gas exchange. Both PTI and VE40 are measures of ventilatory endurance. In a post-hoc analysis that used a threshold of 4 min-1, the WI was highly accurate in predicting weaning outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Integrative weaning index (IWI) = [(Cst,rs)*SaO",
"      <sub>",
"       2",
"      </sub>",
"      ]",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      <span class=\"nowrap\">",
"       [f/VT],",
"      </span>",
"      where Cst,rs is the static compliance (Cst,rs), SaO",
"      <sub>",
"       2",
"      </sub>",
"      is the arterial oxygen saturation (SaO",
"      <sub>",
"       2",
"      </sub>",
"      ), f is the respiratory rate, and VT is the tidal volume. In an observational study, threshold values were determined in 115 patients and then prospectively validated in an additional 216 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/37\">",
"       37",
"      </a>",
"      ]. An IWI &ge;25",
"      <span class=\"nowrap\">",
"       ml/cm",
"      </span>",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/breaths/min/liter",
"      </span>",
"      predicted successful weaning with a sensitivity and specificity of 0.97 and 0.94, respectively. The LR+ and LR- were 16 and 0.03, respectively, indicating that there is a large increase in the probability of weaning success among patients with an IWI &gt;25",
"      <span class=\"nowrap\">",
"       mL/cm",
"      </span>",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/breaths/min/liter,",
"      </span>",
"      as well as a large increase in the probability of weaning failure among patients with an IWI &lt;25",
"      <span class=\"nowrap\">",
"       mL/cm",
"      </span>",
"      <span class=\"nowrap\">",
"       H",
"       <sub>",
"        2",
"       </sub>",
"       O/breaths/min/liter.",
"      </span>",
"      The IWI was more accurate than other weaning predictors. An important limitation of the IWI is the difficulty measuring Cst,rs in a spontaneously breathing patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     APPROACH TO READINESS TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section describes our approach to assessing patients' readiness to wean, which we believe is both practical and evidence-based. We recognize that other reasonable approaches exist.",
"   </p>",
"   <p>",
"    We screen patients daily for readiness to wean. Our screen consists of the following objective clinical criteria (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical criteria'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The cause of the respiratory failure has improved",
"     </li>",
"     <li>",
"      The patient is oxygenating adequately",
"     </li>",
"     <li>",
"      The arterial pH is &gt;7.25",
"     </li>",
"     <li>",
"      The patient is able to initiate an inspiratory effort",
"     </li>",
"     <li>",
"      The patient is hemodynamically stable, without myocardial ischemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef62377 \" href=\"UTD.htm?36/34/37419\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The ability of objective clinical criteria alone to assess patients' readiness to wean (without the aid of a weaning predictor) was demonstrated by two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 304 mechanically ventilated patients compared patients who underwent readiness testing using objective clinical criteria alone to those who underwent readiness testing using objective clinical criteria plus a weaning predictor (the rapid shallow breathing index) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/38\">",
"       38",
"      </a>",
"      ]. The group that used objective clinical criteria alone took one day less to discontinue mechanical ventilation. There was no difference in the total duration of mechanical ventilation, length of stay, or reintubation rate. This trial is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21140?source=see_link&amp;anchor=H4#H4\">",
"       \"Weaning from mechanical ventilation: The rapid shallow breathing index\", section on 'Clinical outcomes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The",
"      <strong>",
"       A",
"      </strong>",
"      wakening and",
"      <strong>",
"       B",
"      </strong>",
"      reathing",
"      <strong>",
"       C",
"      </strong>",
"      ontrolled (ABC) trial screened 336 mechanically ventilated patients daily for adequate oxygenation (SpO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;88 percent while receiving an FiO",
"      <sub>",
"       2",
"      </sub>",
"      &lt;50 percent and PEEP &le;8 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O), hemodynamic stability, and any spontaneous inspiratory effort during a 5 minute period, as well as the absence of agitation, myocardial ischemia, and increased intracranial pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/13\">",
"       13",
"      </a>",
"      ]. Weaning predictors were not measured. Those who passed the screen were immediately shifted to a period of breathing without assistance from the ventilator (ie, a spontaneous breathing trial [SBT]). More than 50 percent of patients who underwent an SBT tolerated it and those who failed the SBT did not suffer any adverse consequences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We use weaning predictors very sparingly. The rare situation in which we consider using a weaning predictor is when a patient has been deemed ready to wean according to clinical criteria, but enough uncertainty lingers that a confirmatory test is desired. This is most pertinent among patients in whom the risk associated with a failed spontaneous trial is significantly elevated. The goal is to identify patients who are not ready to wean in order to avoid the risks of failed weaning. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Purpose of readiness testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The rapid shallow breathing index (RBSI) is our preferred weaning indicator because it is well studied, easy to measure, and no alternative weaning predictor has been shown to be superior to the RSBI. Weaning is initiated for patients who have an RSBI &lt;105",
"    <span class=\"nowrap\">",
"     breaths/min/L",
"    </span>",
"    (measured without ventilatory support), while full ventilatory support is maintained for patients who have an RSBI &gt;105",
"    <span class=\"nowrap\">",
"     breaths/min/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21140?source=see_link\">",
"     \"Weaning from mechanical ventilation: The rapid shallow breathing index\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weaning may involve either an SBT or a gradual reduction in the amount of ventilator support. An SBT is generally preferred, although the gradual reduction may be better in certain situations (eg, a debilitated patient who has been mechanically ventilated for a prolonged period). Methods of weaning are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14423?source=see_link\">",
"     \"Methods of weaning from mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Readiness testing is imperfect and some patients deemed ready to wean will fail. Despite the theoretical risks, failed weaning has not been shown to be harmful if it is well monitored and the patient is returned to full ventilatory support at the first sign of intolerance. In a study of more than 1000 patients who underwent an SBT, only one complication was identified (&lt;0.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/39\">",
"     39",
"    </a>",
"    ]. Another study of 19 patients who underwent an SBT found that low frequency fatigue, which can hinder future weaning attempts, did not occur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/40\">",
"     40",
"    </a>",
"    ]. Finally, an observational study found no difference in mortality when patients who passed their first SBT (followed by successful extubation) were compared with those who failed their first SBT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21112/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discontinuing mechanical ventilation is a two step process that consists of readiness testing and weaning. During readiness testing, objective clinical criteria are used to determine whether a patient is ready to begin weaning. Some clinicians also use physiological tests, known as weaning predictors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The purpose of readiness testing is to identify patients who are ready to wean, since clinicians tend to underestimate the capacity of patients to breathe independently. It is also intended to identify patients who are not ready for weaning, thereby protecting them against the potential risks of premature weaning. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Purpose of readiness testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mechanically ventilated patients should have their readiness to wean assessed daily. We recommend that weaning be initiated on the basis of objective clinical criteria alone, rather than using a weaning predictor or the clinician's subjective impression (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Approach to readiness testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical criteria'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Weaning predictors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reasonable objective clinical criteria are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef62377 \" href=\"UTD.htm?36/34/37419\">",
"       table 1",
"      </a>",
"      ). They include evidence that the cause of the respiratory failure has improved, adequate oxygenation (ie, a",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &ge;150 or an SpO",
"      <sub>",
"       2",
"      </sub>",
"      &ge;90 percent while receiving an FiO",
"      <sub>",
"       2",
"      </sub>",
"      &le;40 percent and a PEEP &le;5 mmHg), an arterial pH &gt;7.25, hemodynamic stability without myocardial ischemia (ie, no pressors or low dose pressors), and the ability to initiate an inspiratory effort. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Numerous weaning predictors have been studied, but none appear to be superior to objective clinical criteria in predicting a patient's readiness to wean. The rapid shallow breathing index (RSBI) is the most extensively studied and popular weaning predictor. It is discussed in detail separately. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Weaning predictors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21140?source=see_link\">",
"       \"Weaning from mechanical ventilation: The rapid shallow breathing index\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Weaning may involve either a period of breathing without ventilator support (ie, a spontaneous breathing trial [SBT]) or a gradual reduction in the amount of ventilator support. An SBT is generally preferred, but the gradual reduction may be better in certain situations. Methods of weaning are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14423?source=see_link\">",
"       \"Methods of weaning from mechanical ventilation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/1\">",
"      Esteban A, Frutos F, Tobin MJ, et al. A comparison of four methods of weaning patients from mechanical ventilation. Spanish Lung Failure Collaborative Group. N Engl J Med 1995; 332:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/2\">",
"      Brochard L, Rauss A, Benito S, et al. Comparison of three methods of gradual withdrawal from ventilatory support during weaning from mechanical ventilation. Am J Respir Crit Care Med 1994; 150:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/3\">",
"      Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002; 287:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/4\">",
"      Funk GC, Anders S, Breyer MK, et al. Incidence and outcome of weaning from mechanical ventilation according to new categories. Eur Respir J 2010; 35:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/5\">",
"      Epstein SK, Nevins ML, Chung J. Effect of unplanned extubation on outcome of mechanical ventilation. Am J Respir Crit Care Med 2000; 161:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/6\">",
"      MacIntyre NR, Cook DJ, Ely EW Jr, et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. Chest 2001; 120:375S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/7\">",
"      Stroetz RW, Hubmayr RD. Tidal volume maintenance during weaning with pressure support. Am J Respir Crit Care Med 1995; 152:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/8\">",
"      Ely EW, Baker AM, Evans GW, Haponik EF. The prognostic significance of passing a daily screen of weaning parameters. Intensive Care Med 1999; 25:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/9\">",
"      H&eacute;bert PC, Blajchman MA, Cook DJ, et al. Do blood transfusions improve outcomes related to mechanical ventilation? Chest 2001; 119:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/10\">",
"      Amoateng-Adjepong Y, Jacob BK, Ahmad M, Manthous CA. The effect of sepsis on breathing pattern and weaning outcomes in patients recovering from respiratory failure. Chest 1997; 112:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/11\">",
"      Coplin WM, Pierson DJ, Cooley KD, et al. Implications of extubation delay in brain-injured patients meeting standard weaning criteria. Am J Respir Crit Care Med 2000; 161:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/12\">",
"      Beuret P, Roux C, Auclair A, et al. Interest of an objective evaluation of cough during weaning from mechanical ventilation. Intensive Care Med 2009; 35:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/13\">",
"      Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet 2008; 371:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/14\">",
"      Krieger BP, Ershowsky PF, Becker DA, Gazeroglu HB. Evaluation of conventional criteria for predicting successful weaning from mechanical ventilatory support in elderly patients. Crit Care Med 1989; 17:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/15\">",
"      Meade M, Guyatt G, Cook D, et al. Predicting success in weaning from mechanical ventilation. Chest 2001; 120:400S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/16\">",
"      Sahn SA, Lakshminarayan S. Bedside criteria for discontinuation of mechanical ventilation. Chest 1973; 63:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/17\">",
"      Multz AS, Aldrich TK, Prezant DJ, et al. Maximal inspiratory pressure is not a reliable test of inspiratory muscle strength in mechanically ventilated patients. Am Rev Respir Dis 1990; 142:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/18\">",
"      Yang KL, Tobin MJ. A prospective study of indexes predicting the outcome of trials of weaning from mechanical ventilation. N Engl J Med 1991; 324:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/19\">",
"      Sassoon CS, Mahutte CK. Airway occlusion pressure and breathing pattern as predictors of weaning outcome. Am Rev Respir Dis 1993; 148:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/20\">",
"      Sassoon CS, Te TT, Mahutte CK, Light RW. Airway occlusion pressure. An important indicator for successful weaning in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1987; 135:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/21\">",
"      Montgomery AB, Holle RH, Neagley SR, et al. Prediction of successful ventilator weaning using airway occlusion pressure and hypercapnic challenge. Chest 1987; 91:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/22\">",
"      Nemer SN, Barbas CS, Caldeira JB, et al. Evaluation of maximal inspiratory pressure, tracheal airway occlusion pressure, and its ratio in the weaning outcome. J Crit Care 2009; 24:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/23\">",
"      Conti G, Montini L, Pennisi MA, et al. A prospective, blinded evaluation of indexes proposed to predict weaning from mechanical ventilation. Intensive Care Med 2004; 30:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/24\">",
"      Jubran A, Tobin MJ. Pathophysiologic basis of acute respiratory distress in patients who fail a trial of weaning from mechanical ventilation. Am J Respir Crit Care Med 1997; 155:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/25\">",
"      Vassilakopoulos T, Routsi C, Sotiropoulou C, et al. The combination of the load/force balance and the frequency/tidal volume can predict weaning outcome. Intensive Care Med 2006; 32:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/26\">",
"      Vassilakopoulos T, Zakynthinos S, Roussos C. The tension-time index and the frequency/tidal volume ratio are the major pathophysiologic determinants of weaning failure and success. Am J Respir Crit Care Med 1998; 158:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/27\">",
"      Fiastro JF, Habib MP, Shon BY, Campbell SC. Comparison of standard weaning parameters and the mechanical work of breathing in mechanically ventilated patients. Chest 1988; 94:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/28\">",
"      Levy MM, Miyasaki A, Langston D. Work of breathing as a weaning parameter in mechanically ventilated patients. Chest 1995; 108:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/29\">",
"      Mohsenifar Z, Hay A, Hay J, et al. Gastric intramural pH as a predictor of success or failure in weaning patients from mechanical ventilation. Ann Intern Med 1993; 119:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/30\">",
"      Hurtado FJ, Ber&oacute;n M, Olivera W, et al. Gastric intramucosal pH and intraluminal PCO2 during weaning from mechanical ventilation. Crit Care Med 2001; 29:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/31\">",
"      Field S, Kelly SM, Macklem PT. The oxygen cost of breathing in patients with cardiorespiratory disease. Am Rev Respir Dis 1982; 126:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/32\">",
"      Hubmayr RD, Loosbrock LM, Gillespie DJ, Rodarte JR. Oxygen uptake during weaning from mechanical ventilation. Chest 1988; 94:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/33\">",
"      Kemper M, Weissman C, Askanazi J, et al. Metabolic and respiratory changes during weaning from mechanical ventilation. Chest 1987; 92:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/34\">",
"      Milic-Emili J. Is weaning an art or a science? Am Rev Respir Dis 1986; 134:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/35\">",
"      Delisle S, Francoeur M, Albert M, et al. Preliminary evaluation of a new index to predict the outcome of a spontaneous breathing trial. Respir Care 2011; 56:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/36\">",
"      Jabour ER, Rabil DM, Truwit JD, Rochester DF. Evaluation of a new weaning index based on ventilatory endurance and the efficiency of gas exchange. Am Rev Respir Dis 1991; 144:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/37\">",
"      Nemer SN, Barbas CS, Caldeira JB, et al. A new integrative weaning index of discontinuation from mechanical ventilation. Crit Care 2009; 13:R152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/38\">",
"      Tanios MA, Nevins ML, Hendra KP, et al. A randomized, controlled trial of the role of weaning predictors in clinical decision making. Crit Care Med 2006; 34:2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/39\">",
"      Ely EW, Bennett PA, Bowton DL, et al. Large scale implementation of a respiratory therapist-driven protocol for ventilator weaning. Am J Respir Crit Care Med 1999; 159:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21112/abstract/40\">",
"      Laghi F, Cattapan SE, Jubran A, et al. Is weaning failure caused by low-frequency fatigue of the diaphragm? Am J Respir Crit Care Med 2003; 167:120.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1652 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21112=[""].join("\n");
var outline_f20_39_21112=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PURPOSE OF READINESS TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Required criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Optional criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical evidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      WEANING PREDICTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rapid shallow breathing index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Oxygenation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Minute ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Maximal inspiratory pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Occlusion pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Work of breathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Gastric mucosal acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Oxygen cost of breathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Integrative indices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      APPROACH TO READINESS TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1652\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1652|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/34/37419\" title=\"table 1\">",
"      Weaning clinical criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/0/44044\" title=\"table 2\">",
"      Weaning predictors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/40/5771\" title=\"table 3\">",
"      Likelihood ratios",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=related_link\">",
"      Evaluating diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=related_link\">",
"      Extubation management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14423?source=related_link\">",
"      Methods of weaning from mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=related_link\">",
"      Physiologic and pathophysiologic consequences of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=related_link\">",
"      Pulmonary barotrauma during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=related_link\">",
"      Tests of respiratory muscle strength",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=related_link\">",
"      Ventilator-associated lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21140?source=related_link\">",
"      Weaning from mechanical ventilation: The rapid shallow breathing index",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_39_21113="Abdominal surgical incisions: Prevention and treatment of complications";
var content_f20_39_21113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Abdominal surgical incisions: Prevention and treatment of complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/39/21113/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/39/21113/contributors\">",
"     Jason S Mizell, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/39/21113/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/39/21113/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/39/21113/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/39/21113/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/39/21113/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound complications are important causes of early and late postoperative morbidity following laparotomy. Surgical wounds in normal, healthy individuals heal through an orderly sequence of physiologic events that include inflammation, epithelialization, fibroplasia, and maturation. Mechanical failure or failure of wound healing at the surgical site can lead to disruption of the closure leading to seroma, hematoma, wound dehiscence or hernia. Other complications include surgical site infection and nerve injury. This topic will review prevention and treatment of complications of abdominal surgical incisions.",
"   </p>",
"   <p>",
"    Techniques for making and closing abdominal incisions to achieve an optimal outcome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link\">",
"     \"Principles of abdominal wall closure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30265?source=see_link\">",
"     \"Principles of abdominal wall incisions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEMATOMA AND SEROMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematoma and seroma are collections of blood and serum, respectively. Hematomas are more common than seromas, and usually result from failure of primary hemostasis or a bleeding diatheses (eg, anticoagulation). Hematomas and seromas can cause the incision to separate and predispose to wound infection since bacteria can gain access to deeper layers and multiply uninhibited in the stagnant fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations usually appear a few days after surgery but can also be delayed. Collections of blood or serum in the wound may be asymptomatic or manifest as swelling, pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drainage. If the collection is infected, fever, erythema, wound induration and leukocytosis are also likely. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Surgical site infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnosis can usually be made by inspection and palpation of the wound. If the examination is in question, ultrasound or computed tomography (CT) is useful for identifying a fluid collection, if present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small hematomas and seromas can be managed expectantly, while large collections should be drained. For symptomatic hematomas, the wound is opened partially or completely under sterile conditions. If there is no evidence of infection, the wound can be closed immediately. For suspected seroma, aspiration under sterile conditions may be all that is required.",
"   </p>",
"   <p>",
"    More commonly after exploration, the wound is packed until granulation tissue is present and then closed in a delayed fashion or the wound is allowed to heal by secondary intention. Delayed closure significantly reduces healing time compared with healing by secondary intention [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H456663840#H456663840\">",
"     \"Basic principles of wound management\", section on 'Wound packing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H55268797#H55268797\">",
"     \"Basic principles of wound management\", section on 'Wound closure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meticulous hemostasis during surgery is essential. Procedures that are associated with a potential for collections of blood and serum in the subcutaneous tissues may benefit from prophylactic wound drainage, especially when large potential dead spaces are created (ie, repair of large ventral hernia, post-mastectomy). The prevention of fluid collection and subsequent infection is the primary aim. Obesity is a risk factor for local wound complications and drain placement may reduce complications but is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/3\">",
"     3",
"    </a>",
"    ]. The use of drains in abdominal wound closure is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link&amp;anchor=H27#H27\">",
"     \"Principles of abdominal wall closure\", section on 'Drains'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SURGICAL SITE INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection occurs in about 4 percent of clean wounds and 35 percent of grossly contaminated wounds. The Center for Disease Control definitions of and criteria for surgical site infection are shown in the figures (",
"    <a class=\"graphic graphic_figure graphicRef80661 \" href=\"UTD.htm?34/49/35603\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef79765 \" href=\"UTD.htm?34/2/34861\">",
"     table 1",
"    </a>",
"    ). Patient-specific risk factors for surgical site infection include: diabetes, obesity, immunosuppression, cardiovascular disease, smoking, cancer, previous surgery, malnutrition and prior irradiation. Technical risk factors are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef62246 \" href=\"UTD.htm?13/21/13660\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of wound infection is clinical. Symptoms include localized erythema, induration, warmth, and pain at the incision site. Purulent wound drainage and separation of the wound may occur. Some patients will have systemic evidence of their infection such as fever and leukocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=see_link\">",
"     \"Postoperative fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Necrotizing fasciitis, perhaps the most serious wound infection, can be lethal and is a surgical emergency. It is characterized by a copious dishwater-like drainage, dusky and friable subcutaneous tissue, and pale, devitalized fascia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infected wounds are opened, explored, drained, irrigated, debrided, and dressed open. If fascial disruption is suspected, drainage should be performed in the operating room. Once the infection has cleared and granulation tissue is apparent, the wound can be closed secondarily. The need for antibiotic therapy is determined by the extent of the infection, presence of systemic manifestations, and comorbidities of the patient (eg, immunocompromise, diabetes, chronic steroids). (See",
"    <a class=\"local\" href=\"#H174061372\">",
"     'Antibiotic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174061383\">",
"    <span class=\"h3\">",
"     Incision and drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A syringe filled with saline solution can be used to apply irrigation under pressure to remove loose dead tissue, exudate, and clots. Saline is favored because it is an isotonic solution and does not interfere with the normal healing process; however, tap water has also been used for wound care in the home or ambulatory setting with good results [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H456665404#H456665404\">",
"     \"Basic principles of wound management\", section on 'Irrigation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mechanical debridement is performed with forceps and scalpel or scissors. All foreign bodies and devitalized tissue are excised because they can delay healing and promote infection. Debridement is discontinued once necrotic tissue has been removed and granulation tissue is present. Enzymatic agents are also available and are useful when manual debridement is not possible [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H55268712#H55268712\">",
"     \"Basic principles of wound management\", section on 'Wound debridement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deep wounds may require packing. Gauze is moistened with normal saline and placed into the wound and covered with dry layers of gauze [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/6\">",
"     6",
"    </a>",
"    ]. When the gauze is removed (preferably before it dries out), necrotic tissue is removed with it, which provides a form of debridement. However, once debridement is no longer necessary, the packing material should be changed from gauze to one that is less traumatic to the developing granulation tissue and new epithelial cells. Dressing changes may be required up to three times daily and are continued until the wound surface is mostly covered by granulation tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H456663840#H456663840\">",
"     \"Basic principles of wound management\", section on 'Wound packing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174061366\">",
"    <span class=\"h3\">",
"     Wound dressings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dressings that maintain moisture and warmth facilitate healing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/6\">",
"     6",
"    </a>",
"    ]. Retention of moisture is important because wound fluids contain tissue growth factors that facilitate reepithelialization and promote autolytic debridement. Once necrotic tissue has been removed and the wound is granulating, these dressings can be changed once a day or every other day in order to avoid disturbing the healing process.",
"   </p>",
"   <p>",
"    The ideal dressing for healing wounds by secondary intention should absorb exudate without leakage, be impermeable to water and bacteria, lack particulate contaminants that could be left in the wound upon removal, and is not traumatic to granulation tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/7\">",
"     7",
"    </a>",
"    ]. Many choices are available without good data to recommend one over another (",
"    <a class=\"graphic graphic_table graphicRef60931 \" href=\"UTD.htm?31/53/32604\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H55268776#H55268776\">",
"     \"Basic principles of wound management\", section on 'Wound dressings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Negative pressure wound therapy (also called vacuum-assisted wound closure) can be used for wounds that have a clean, granulating base. The negative pressure reduces excess fluid accumulation and, with time, the size of large complex wounds. It also helps protect the patient&rsquo;s skin from irritation from frequent dressing changes since it is only changed every 3 to 5 days. The techniques for placement and care of wounds with these devices are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link\">",
"     \"Negative pressure wound therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174061372\">",
"    <span class=\"h3\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound infections associated with cellulitis alone (ie, no fluctuance) can be treated with a course of antibiotics without open drainage. Superficial incisional infections that have been opened can usually be managed without antibiotics. Topical agents (eg, povidone-iodine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/23/29042?source=see_link\">",
"     sodium hypochlorite",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    ) do not offer any advantage over drainage and debridement and should be avoided since they may be toxic to fibroblasts and, as a result, impede wound healing.",
"   </p>",
"   <p>",
"    For more severe infections, as evidenced by extension into adjacent tissue or systemic signs, empiric treatment is started using broad spectrum antibiotics with coverage of gram positive cocci from the skin as well as the expected flora at the site of operation. Definitive antimicrobial treatment is guided by the clinical response of the patient and, when available, results of gram stain, wound culture, and sensitivity. However, wound swab cultures often reveal polymicrobial growth, making it difficult to distinguish colonization from true infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37761?source=see_link\">",
"     \"Clinical microbiology review: Wound, skin, and soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174061378\">",
"    <span class=\"h3\">",
"     Delayed closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, wounds that have been opened due to infection are left to heal by secondary intention. However, delayed closure is safe and effective, with only a 5 percent incidence of reexploration for reinfection. Closure significantly shortens the healing time [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgeons can modify rates of infection with meticulous surgical technique and preventive measures including avoiding surgery in patients with active infection, antibiotic prophylaxis, proper skin preparation, and maintenance of sterile conditions (",
"    <a class=\"graphic graphic_table graphicRef58579 \" href=\"UTD.htm?17/31/17916\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/9\">",
"     9",
"    </a>",
"    ]. Preventive measures to control surgical site infection are discussed elsewhere. Antibiotic prophylaxis is briefly discussed below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174061904\">",
"    <span class=\"h3\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention",
"    <span class=\"nowrap\">",
"     (CDC/USDHHS)",
"    </span>",
"    has published guidelines for prevention of surgical site infections. These guidelines can be accessed at the Centers for Disease Control and Prevention's web site [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal of antimicrobial prophylaxis is to reduce the risk of bacterial contamination to a level that cannot overwhelm the body's defense mechanisms. Prophylactic antibiotics should be administered before the creation of an abdominal incision (",
"    <a class=\"graphic graphic_table graphicRef79097 \" href=\"UTD.htm?22/46/23275\">",
"     table 5",
"    </a>",
"    ) and should be appropriate for the type of surgery (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/11\">",
"     11",
"    </a>",
"    ]. Commonly used agents include:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=see_link\">",
"     cefotetan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . Alternative agents in penicillin-allergic patients include vancomycin or clindamycin, intravenously. If surgery exceeds four hours or blood loss exceeds 1500 mL, a second dose of antibiotics should be administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Antimicrobial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174062184\">",
"    <span class=\"h3\">",
"     Surgical technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical technique that avoids excessive tissue injury and ischemia while providing adequate hemostasis is the first step toward preventing infection. Other surgical techniques that may impact infection rates include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Use of electrocautery",
"      </strong>",
"      &ndash; Controversy persists regarding the choice of scalpel or electrocautery for incision of the subcutaneous tissues. Multiple strokes in the incision, whether by scalpel or electrosurgery, result in greater tissue damage. Excessive dissection of the subcutaneous tissues also increases the dead space which can predispose to fluid collection and subsequent infection. We prefer to use a scalpel for the skin incision and electrosurgery for the subcutaneous tissue and fascia.",
"      <br/>",
"      <br/>",
"      Electrosurgery is associated with varying degrees of thermal damage to tissue. A concern is that the resulting necrotic tissue will become a focus of infection and potentially weaken the repair. However, when non-modulated (cutting) current is used with a peak voltage of 200 volts, tissue is vaporized with minimal thermal spread beyond the point of incision, thus producing tissue damage no worse than that resulting from a sharp scalpel. The use of electrosurgery rather than a scalpel for both incision of the skin and underlying tissues is also accepted. This practice is supported by a systematic review and metaanalysis comparing electrosurgery versus scalpel for incision of skin and subcutaneous tissue, and showed no differences in the incidence of wound infection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/12\">",
"       12",
"      </a>",
"      ]. Electrosurgery may be associated with less pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30265?source=see_link&amp;anchor=H10#H10\">",
"       \"Principles of abdominal wall incisions\", section on 'Skin incision'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Closure of subcutaneous tissue",
"      </strong>",
"      &ndash; Closure of the subcutaneous tissues following abdominal fascial closure has been studied as it relates to the incidence of wound infection in certain circumstances. In the general surgical literature, there is no evidence to suggest an increased incidence of infectious or noninfectious wound complications when the subcutaneous tissues are not sutured [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/13\">",
"       13",
"      </a>",
"      ]. However, in the obstetric literature, there is evidence that closure of Camper's fascia at the time of cesarean delivery reduces the incidence of superficial wound disruption, particularly in patients with at least 2 cm of subcutaneous fat [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. A trial of abdominal hysterectomy patients showed similar results [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/16\">",
"       16",
"      </a>",
"      ]. Closure of the subcutaneous tissue at the time of hysterectomy in women with greater than 2.5 centimeters of subcutaneous fat resulted in a lower incidence of wound disruption. In these studies, superficial disruption often was associated with seroma, hematoma, or infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link&amp;anchor=H19#H19\">",
"       \"Principles of abdominal wall closure\", section on 'Subcutaneous'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Skin closure",
"      </strong>",
"      &ndash; Staples are less likely to obscure wound drainage and impending separation than subcuticular sutures. If part of the wound becomes infected, only a few select staples need be removed without opening the entire skin incision as generally occurs once a subcuticular suture is cut. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link&amp;anchor=H20#H20\">",
"       \"Principles of abdominal wall closure\", section on 'Skin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Delayed closure",
"      </strong>",
"      &ndash; Delayed closure and healing by secondary intention are equally effective alternatives in cases of infection or wound contamination [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/17\">",
"       17",
"      </a>",
"      ]. A trial that compared delayed closure to healing by secondary intention in patients with superficial wound dehiscence showed that delayed closure resulted in faster healing time and fewer postoperative visits [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/1\">",
"       1",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Delayed closure may be accomplished under local anesthesia using sutures or a nonocclusive adhesive bandage. Optimally, closure should be performed after granulation tissue has started to form, normally in four to five days, and before wound contraction has begun. Closure beyond 10 postoperative days is associated with greater risk of wound infection, making secondary intention preferable in this circumstance [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Hypothermia",
"      </strong>",
"      &ndash; Body temperature and tissue oxygenation may significantly impact wound healing and the risk of surgical site infections. Perioperative hypothermia by one degree Celsius triggers thermoregulatory vasoconstriction, which decreases tissue oxygen tension and directly impairs antibody- and cell-mediated immune defenses. Reduced availability of tissue oxygen interferes with collagen deposition, which decreases tensile wound strength. Suppression of mitogen-induced activation of lymphocytes and reduced production of cytokines, IL-1beta and IL-2, may be responsible for the increased risk of surgical site infections.",
"      <br/>",
"      <br/>",
"      Clinically, core hypothermia triples the incidence of surgical site infections following colon resection and extends the duration of hospitalization by 20 percent. In the absence of a specific indication for therapeutic hypothermia, normothermia should be maintained in the perioperative period. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33834?source=see_link&amp;anchor=H1324457038#H1324457038\">",
"       \"Overview of complications occurring in the post-anesthesia care unit\", section on 'Hypothermia or hyperthermia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Adjunctive therapies",
"      </strong>",
"      &ndash; While delivery of adequate oxygen through the microcirculation is vital for optimal healing and resistance to infection, the benefit of supplemental oxygen in the perioperative period has not been substantiated. Surgical patients should continue to receive oxygen supplementation with cardiorespiratory physiology as the principal determinant.",
"      <br/>",
"      <br/>",
"      Preoperative and postoperative hyperbaric oxygen therapy may be beneficial in situations where local injury, poor microcirculation or infection, particularly associated with anaerobic organisms, compromise tissue healing. However, definitive benefit of this therapy is yet to be established, and the indication for hyperbaric oxygen therapy must be individualized [",
"      <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H369375086#H369375086\">",
"       \"Basic principles of wound management\", section on 'Hyperbaric oxygen therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FASCIAL DEHISCENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fascial disruption is due to abdominal wall tension overcoming tissue or suture strength, or knot security. It can occur early or late in the postoperative period, and involve a portion of the incision (ie, partial dehiscence) or the entire incision (ie, complete fascial dehiscence). The incidence of fascial disruption ranges from 0.4 to 3.5 percent depending upon the type of surgery performed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Despite improved perioperative care and stronger suture materials, the incidence and morbidity of fascial dehiscence are largely unchanged.",
"   </p>",
"   <p>",
"    With early fascial dehiscence, the skin closure may be intact depending upon the method of closure (ie, staples, sutures); the patient, nevertheless, is at risk for evisceration. Early postoperative fascial dehiscence is a surgical emergency. The late complication of fascial disruption is incisional hernia. Incisional hernia is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of abdominal hernias\", section on 'Incisional hernia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Patient risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Independent risk factors for fascial disruption in one risk model included age, male sex, chronic pulmonary disease, ascites, anemia, emergency surgery, postoperative coughing, wound infection, and the type of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/24\">",
"     24",
"    </a>",
"    ]. Other factors include malignancy, obesity, hypoalbuminemia (poor nutrition), sepsis, and chronic glucocorticoid therapy (",
"    <a class=\"graphic graphic_table graphicRef50873 \" href=\"UTD.htm?13/28/13771\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/25\">",
"     25",
"    </a>",
"    ]. Diabetes mellitus alone was not a risk factor for fascial dehiscence in these observational studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H573601170\">",
"    <span class=\"h2\">",
"     Technical factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fascial dehiscence may also be related to technique. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30265?source=see_link\">",
"     \"Principles of abdominal wall incisions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Incisional factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tension on an incision is proportional to its length [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/26\">",
"     26",
"    </a>",
"    ]. Herniation is more common when the incision length exceeds 18 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/27\">",
"     27",
"    </a>",
"    ]. It was thought that longitudinal incisions were at greater risk of dehiscence than transverse incisions. However, it is difficult to make legitimate comparisons since longitudinal incisions are more likely to be performed in cases of hemorrhage, trauma, sepsis, multiorgan disease, previous surgery, previous radiation therapy, and malignancy. Randomized trials comparing paramedian, transverse, and midline incisions have reported no significant differences in the frequency of dehiscence or herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Suture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main causes of wound separation are failure of suture to remain anchored in the fascia, suture breakage, knot failure, and excessive stitch interval which allows protrusion of viscera [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/31\">",
"     31",
"    </a>",
"    ]. In up to 95 percent of abdominal wound dehiscences, the sutures and knots are intact, but the suture has pulled through the fascia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. This is usually the result of fascial necrosis from sutures being placed too close to the edge or under too much tension. Sutures should be about 1 cm from the wound edge and about 1 cm from the adjacent suture to ensure that the tissue is strong enough to hold the suture. For continuous closure, the total length of the suture should be approximately four times the length of the incision [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link&amp;anchor=H17#H17\">",
"     \"Principles of abdominal wall closure\", section on 'Technique'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To minimize the risk of incisional hernia, elective midline abdominal closure (first operation or reoperation) should be performed with continuous, slowly absorbable sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link&amp;anchor=H22#H22\">",
"     \"Principles of abdominal wall closure\", section on 'Midline'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms of a complete dehiscence include profuse serosanguinous drainage, often preceded by a popping sensation and an incisional bulge exacerbated by Valsalva maneuvers. Most dehiscences occur 4 to 14 days after surgery, with a mean of 8 days. The diagnosis can be made based upon clinical grounds in the majority of cases.",
"   </p>",
"   <p>",
"    The absence of a healing ridge in a laparotomy incision by postoperative day five can be a sign of impaired healing and impending disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/21\">",
"     21",
"    </a>",
"    ]. In one series, 1240 of 1249 patients without dehiscence had a palpable ridge, compared with 17 patients with dehiscence without a ridge [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Imaging studies, such as ultrasonography and computed tomography, are used when the diagnosis is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When fascial disruption is suspected, wound exploration should be performed in the operating room. Complete fascial dehiscence is associated with a mortality rate of 10 percent, and is a surgical emergency.",
"   </p>",
"   <p>",
"    At the bedside, a moist dressing is placed over the wound and a binder can be placed around the patient's abdomen to prevent overt evisceration on the way to the operating room. A binder should",
"    <strong>",
"     not",
"    </strong>",
"    be used in cases of complete dehiscence and evisceration due to the potential for bowel injury.",
"   </p>",
"   <p>",
"    Once the wound is opened, the edges are thoroughly debrided. A mass closure with continuous, slowly absorbable suture should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/35\">",
"     35",
"    </a>",
"    ]. Depending upon the circumstance, the skin may or may not be left open. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link&amp;anchor=H22#H22\">",
"     \"Principles of abdominal wall closure\", section on 'Midline'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The method of fascial closure is a critical aspect of incisional closure, as this provides the majority of wound strength during healing. Two metaanalyses related to abdominal fascial closure suggest an optimal technique for closure of abdominal surgical wounds includes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/36,38\">",
"     36,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of a simple running technique",
"     </li>",
"     <li>",
"      Use of #1 or #2 delayed absorbable suture",
"     </li>",
"     <li>",
"      Use of mass closure to incorporate all layers of the abdominal wall (except skin)",
"     </li>",
"     <li>",
"      Taking wide tissue bites (about 1 cm)",
"     </li>",
"     <li>",
"      Use of a short stitch interval (about 1 cm)",
"     </li>",
"     <li>",
"      Use of a suture length to wound length ratio of 4 to 1",
"     </li>",
"     <li>",
"      Use of non-strangulating tension on the suture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Continuous mass closure or interrupted Smead-Jones closure (vertical mattress) with permanent or delayed absorbable suture are both safe and effective. Most midline closures should be performed with continuous mass closure supported by several recent metaanalyses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link&amp;anchor=H22#H22\">",
"     \"Principles of abdominal wall closure\", section on 'Midline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Internal or external retention sutures (",
"    <a class=\"graphic graphic_figure graphicRef70261 graphicRef58213 graphicRef68915 graphicRef67727 \" href=\"UTD.htm?24/25/24986\">",
"     figure 2A-D",
"    </a>",
"    ) are frequently used to reapproximate the fascial edges after a postoperative fascial dehiscence has occurred. The exact suture and distance between each suture is not well defined. Although past observational studies felt there was a benefit to retention sutures, this practice has been called into question [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/39\">",
"     39",
"    </a>",
"    ]. A trial that randomly assigned 95 patients at risk for wound failure to conventional mass closure with or without retention sutures found significantly increased pain and local complications in patients closed with retention sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/40\">",
"     40",
"    </a>",
"    ]. No long-term follow-up with respect to fascial disruption or hernia development was provided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H607392140\">",
"    <span class=\"h3\">",
"     Lifting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperatively, patients are commonly counseled to avoid heavy lifting following laparotomy to prevent wound dehiscence. This is based upon the concern that an increased intraabdominal pressure can result in wound disruption, but there are few data regarding how much weight is safe to lift. Intraabdominal pressure depends upon the amount of weight lifted and the position of the person relative to the object lifted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. As an example, in one study, intraabdominal pressure was measured using a rectal pressure transducer for a range of activities [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/42\">",
"     42",
"    </a>",
"    ]. Many activities, such as lifting 8, 13, and 20 lbs from a counter; lifting 8 or 13 lbs from the floor; climbing stairs; walking briskly; or doing abdominal crunches did",
"    <strong>",
"     not",
"    </strong>",
"    increase intraabdominal pressure more than standing up from a seated position.",
"   </p>",
"   <p>",
"    Nevertheless, we suggest patients avoid heavy lifting (&gt;13 pounds of weight from the floor) for four to six weeks following abdominal surgery to minimize stress on the healing fascia. If the patient cannot easily lift an object with one hand, help should be sought.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174061632\">",
"    <span class=\"h1\">",
"     NERVE INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve injury can lead to unexpected and distressing symptoms following an otherwise successful operation. Pain, loss of sensation, and abdominal wall weakness are the most common symptoms. Three mechanisms of nerve injury occur: transection (from incision), entrapment (from fascia closure), and",
"    <span class=\"nowrap\">",
"     compression/stretching",
"    </span>",
"    (from retraction of tissues or patient positioning). Local nerve injury leading to chronic incisional discomfort is well recognized, but not all chronic incisional pain is due solely to nerve injury. &nbsp;",
"   </p>",
"   <p>",
"    Nerve injuries associated with pelvic surgery and hernia surgery are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=see_link&amp;anchor=H21#H21\">",
"     \"Nerve injury associated with pelvic surgery\", section on 'Prevention of nerve injury'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9465?source=see_link\">",
"     \"Inguinal and femoral hernia repair: Open techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SPECIAL SITUATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Morbid obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity complicates incision selection because exposure is compromised, operating may be difficult, and wound healing may be compromised. Obesity is associated with an increased incidence of wound infection, hematoma formation, incisional hernia, and medical complications.",
"   </p>",
"   <p>",
"    Morbid obesity, defined as body mass index greater than 40, often results in a large protruding panniculus which presents an especially difficult technical problem. Topography of the abdominal wall is distorted, displacing the umbilicus caudally in a position that does not accurately estimate the sacral promontory.",
"   </p>",
"   <p>",
"    Whether a transverse or longitudinal incision is superior in the obese patient remains a controversial issue. However, placing the incision in a deep transverse skin crease, which often contains macerated skin and a high concentration of microorganisms, may increase the risk of infection, and should be avoided. Self-retaining retractors (",
"    <a class=\"graphic graphic_figure graphicRef59242 graphicRef79154 \" href=\"UTD.htm?10/10/10409\">",
"     figure 3A-B",
"    </a>",
"    ) aid exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In obese patients without a significant panniculus, traditional midline or transverse incisions can be used and extended, as needed, around the umbilicus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, to facilitate lower abdominal incisions in patients with a large panniculus, a low midline (",
"    <a class=\"graphic graphic_figure graphicRef63063 \" href=\"UTD.htm?2/53/2896\">",
"     figure 4",
"    </a>",
"    ) or transverse (",
"    <a class=\"graphic graphic_figure graphicRef50505 \" href=\"UTD.htm?13/59/14257\">",
"     figure 5",
"    </a>",
"    ) incision can be made with after pulling the panniculus cephalad [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supraumbilical incisions can be made retracting the panniculus downward (",
"    <a class=\"graphic graphic_figure graphicRef68836 \" href=\"UTD.htm?29/28/30144\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Panniculectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panniculectomy may alleviate problems of surgical exposure, reduce operating time and reduce postoperative problems with wound healing. Panniculectomy facilitates surgery when adipose tissue is so thick that even the longest instruments cannot reach the site of dissection and when the abdomen hangs down over the symphysis and onto the thighs, thus increasing the risk of poor wound healing. Panniculectomy is typically performed in association with the planned abdominal operation typically by a plastic surgeon, and on occasion by a general surgeon well-versed with the procedure. The details of the technique are beyond the scope of this topic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation effects can be divided into acute and chronic reactions. The acute reaction consists of rapid cessation of mitotic activity, followed by cellular swelling. Edema develops in the walls of small vessels and connective tissue becomes edematous and congested because of dilated and engorged lymphatic channels and small vessels. Radiation inhibits differentiation of fibroblast from mesenchymal cells and proliferation of endothelial cells into vascular buds. If the injury is lethal, cellular dissolution and focal necrosis may be seen.",
"   </p>",
"   <p>",
"    Chronic radiation injury is caused by progressive vascular injury, a small vessel endarteritis. Endothelial swelling and proliferation narrows the vessel lumen, which restricts blood flow and may cause thrombosis. Similar effects occur in lymphatic channels. The supply of oxygen and nutrients is reduced to critical concentrations. The humoral and cellular immune defense systems function inefficiently. Proliferation of fibrous tissue causes the skin of the abdominal wall to lose suppleness, harden, and become atrophic, manifested as a shiny appearance with loss of the skin appendages. The skin becomes pigmented and telangiectasias develop [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/47\">",
"     47",
"    </a>",
"    ]. These changes, more common with orthovoltage radiation techniques than newer linear accelerators, are progressive over several years, and never heal or resolve.",
"   </p>",
"   <p>",
"    Patients undergoing radiation therapy have a window of vulnerability to toxic effects. If 2.5 Gy is administered 24 hours before surgery, there is little impact on wound repair. However, the same dose administered 36 hours after surgery will maximally retard neovascularization and normal tissue contraction.",
"   </p>",
"   <p>",
"    Radiation effects are more harmful to an open wound than a closed wound; this effect diminishes five to seven days after the incision is made. A wound that has completely epithelialized and has no fluid or blood collection can be irradiated one week postoperatively without negative effects. Radiation has minimal effects on a mature wound; however, radiotherapy of an infected wound will result in formation of a chronic radiation ulcer. If bowel adhesions limit peristalsis, significant bowel injury may occur.",
"   </p>",
"   <p>",
"    Cancer has little direct effect on wound healing or fascial disruption, but associated poor nutrition resulting from limited intake or cancer-related compromised bowel function may slow the healing process. In addition, incisions placed in a previous irradiation field may heal poorly due to radiation-induced endarteritis. Cancer patients are more likely to have wound contamination from an opened viscus or intraabdominal abscess, and postoperative ileus or collection of ascites may stress the fresh wound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incision placement and timing may be modified to reduce the risk of wound complications. If possible, incisions should be placed outside the intended radiation field. Alternatively, surgery performed four to six weeks after radiotherapy will display relatively normal healing because postoperative inflammation is subsiding and blood supply is still adequate. Over time, the impact of diminished microcirculation from radiation presents an obstacle to wound healing and the risk of surgery rises logarithmically as the dose of irradiation increases.",
"   </p>",
"   <p>",
"    Irradiated tissue may not have sufficient blood supply to withstand multiple incisions without necrosis. Therefore, skin incisions must never be crossed or made parallel in a field of irradiated tissue because of significantly increased risk of skin necrosis, poor healing, and infection. Pain in irradiated wounds may be from ischemia. Because of susceptibility to any type of injury, any insult may trigger a cycle of necrosis and infection.",
"   </p>",
"   <p>",
"    Patients who have undergone preoperative radiation also have delayed healing, reduced tensile strength, and increased risk of infection. The increased risk of dehiscence warrants a closure technique utilizing permanent suture materials, which have been shown to reduce wound complications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/46\">",
"     46",
"    </a>",
"    ]. Delayed absorbable synthetic suture also may be appropriate for some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/39/21113/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link\">",
"     \"Principles of abdominal wall closure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174061205\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical wounds in normal individuals heal through an orderly sequence of physiologic events. Mechanical failure or failure of wound healing at the surgical site can lead to disruption of the closure leading to wound complications. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematoma and seroma are collections of blood and serum, respectively, and can cause the incision to separate, increasing the risk of wound infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hematoma and seroma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for surgical site infection include smoking, diabetes, malnutrition, cancer, obesity, immunosuppression, cardiovascular disease, prior incision, and irradiation at the surgical site. Meticulous surgical technique that avoids excessive tissue injury and ischemia while providing adequate hemostasis are important for preventing infection. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Surgical site infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infected wounds are opened, explored, drained, irrigated, debrided and dressed open. If fascial disruption is suspected, drainage should be performed in the operating room. The severity of the infection determines the need for antibiotic therapy. Once the infection has cleared and granulation tissue is apparent, the wound can be closed secondarily or allowed to heal by secondary intention. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgeons can modify rates of wound infection with preventive measures that include avoiding surgery in patients with active infection, antibiotic prophylaxis, proper skin preparation and maintenance of sterile conditions intraoperatively. Proper surgical technique with gentle tissue handling and a secure closure that does not cause tissue ischemia are equally important. (See",
"      <a class=\"local\" href=\"#H174062184\">",
"       'Surgical technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fascial disruption is due to abdominal wall tension overcoming tissue or suture strength, or knot security. It can occur early or late in the postoperative period. With early fascial dehiscence, the skin closure may be intact depending upon the method of closure (ie, staples, sutures). The patient is at risk for evisceration and early postoperative fascial dehiscence is a surgical emergency. The late complication of fascial disruption is incisional hernia which can lead to bowel obstruction, ischemia and even death. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Fascial dehiscence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obesity complicates abdominal surgery and is associated with an increased incidence of wound infection, hematoma formation, and incisional hernia. Transverse incision, supraumbilical incision or, occasionally, panniculectomy are techniques to manage the obese patient with a large pannus. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Morbid obesity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Irradiated skin is also associated with an increased incidence of wound breakdown. Where possible, incisions should be placed outside the field of future or past radiation. Skin incisions should not be crossed or made parallel in a field of previously irradiated tissue due to a significantly increased risk of poor healing, infection, and, potentially, skin necrosis. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Radiation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/1\">",
"      Dodson MK, Magann EF, Meeks GR. A randomized comparison of secondary closure and secondary intention in patients with superficial wound dehiscence. Obstet Gynecol 1992; 80:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/2\">",
"      Walters MD, Dombroski RA, Davidson SA, et al. Reclosure of disrupted abdominal incisions. Obstet Gynecol 1990; 76:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/3\">",
"      Al-Inany H, Youssef G, Abd ElMaguid A, et al. Value of subcutaneous drainage system in obese females undergoing cesarean section using pfannenstiel incision. Gynecol Obstet Invest 2002; 53:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/4\">",
"      Fernandez R, Griffiths R, Ussia C. Water for wound cleansing. Cochrane Database Syst Rev 2002; :CD003861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/5\">",
"      Steed DL. Debridement. Am J Surg 2004; 187:71S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/6\">",
"      Ovington LG. Hanging wet-to-dry dressings out to dry. Home Healthc Nurse 2001; 19:477.",
"     </a>",
"    </li>",
"    <li>",
"     Sharp CA, McLaws M. Wound dressings for surgical sites [protocol]. In: The Cochrane Library, 1, 2002. Chichester, UK: John Wiley &amp; Sons, Ltd. CD003091.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/8\">",
"      Vermeulen H, Ubbink D, Goossens A, et al. Dressings and topical agents for surgical wounds healing by secondary intention. Cochrane Database Syst Rev 2004; :CD003554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/9\">",
"      Cruse PJ, Foord R. The epidemiology of wound infection. A 10-year prospective study of 62,939 wounds. Surg Clin North Am 1980; 60:27.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/ncidod/dhqp/guidelines.html (Accessed on October 07, 2010).",
"    </li>",
"    <li>",
"     ACOG Practice Bulletin. Clinical management guidelines for obstetricians and gynecologists. ACOG Practice Bulletin 23. American College of Obstetricians and Gynecologists, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/12\">",
"      Ahmad NZ, Ahmed A. Meta-analysis of the effectiveness of surgical scalpel or diathermy in making abdominal skin incisions. Ann Surg 2011; 253:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/13\">",
"      Paral J, Ferko A, Varga J, et al. Comparison of sutured versus non-sutured subcutaneous fat tissue in abdominal surgery. A prospective randomized study. Eur Surg Res 2007; 39:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/14\">",
"      Del Valle GO, Combs P, Qualls C, Curet LB. Does closure of Camper fascia reduce the incidence of post-cesarean superficial wound disruption? Obstet Gynecol 1992; 80:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/15\">",
"      Naumann RW, Hauth JC, Owen J, et al. Subcutaneous tissue approximation in relation to wound disruption after cesarean delivery in obese women. Obstet Gynecol 1995; 85:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/16\">",
"      Kore S, Vyavaharkar M, Akolekar R, et al. Comparison of closure of subcutaneous tissue versus non-closure in relation to wound disruption after abdominal hysterectomy in obese patients. J Postgrad Med 2000; 46:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/17\">",
"      Loudon MA, Barua JM. A novel and convenient method of delayed primary skin closure for grossly contaminated abdominal wounds. J R Coll Surg Edinb 1994; 39:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/18\">",
"      Cohn SM, Giannotti G, Ong AW, et al. Prospective randomized trial of two wound management strategies for dirty abdominal wounds. Ann Surg 2001; 233:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/19\">",
"      Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. N Engl J Med 1996; 334:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/20\">",
"      Pryor KO, Fahey TJ 3rd, Lien CA, Goldstein PA. Surgical site infection and the routine use of perioperative hyperoxia in a general surgical population: a randomized controlled trial. JAMA 2004; 291:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/21\">",
"      Carlson MA. Acute wound failure. Surg Clin North Am 1997; 77:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/22\">",
"      Baggish MS, Lee WK. Abdominal wound disruption. Obstet Gynecol 1975; 46:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/23\">",
"      Pratt J. Wound healing: evisceration. Am J Obstet Gynecol 1973; 132:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/24\">",
"      van Ramshorst GH, Nieuwenhuizen J, Hop WC, et al. Abdominal wound dehiscence in adults: development and validation of a risk model. World J Surg 2010; 34:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/25\">",
"      Pavlidis TE, Galatianos IN, Papaziogas BT, et al. Complete dehiscence of the abdominal wound and incriminating factors. Eur J Surg 2001; 167:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/26\">",
"      Sloan GA. A new upper abdominal incision. Surg Gynecol Obstet 1927; 45:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/27\">",
"      Ellis H, Bucknall TE, Cox PJ. Abdominal incisions and their closure. Curr Probl Surg 1985; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/28\">",
"      Greenall MJ, Evans M, Pollock AV. Midline or transverse laparotomy? A random controlled clinical trial. Part I: Influence on healing. Br J Surg 1980; 67:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/29\">",
"      Ellis H, Coleridge-Smith PD, Joyce AD. Abdominal incisions--vertical or transverse? Postgrad Med J 1984; 60:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/30\">",
"      Sanders RJ, DiClementi D. Principles of abdominal wound closure. II. Prevention of wound dehiscence. Arch Surg 1977; 112:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/31\">",
"      Greenburg AG, Saik RP, Peskin GW. Wound dehiscence. Pathophysiology and prevention. Arch Surg 1979; 114:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/32\">",
"      Bartlett LC. Pressure necrosis is the primary cause of wound dehiscence. Can J Surg 1985; 28:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/33\">",
"      Herrmann JB. Changes in tensile strength and knot security of surgical sutures in vivo. Arch Surg 1973; 106:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/34\">",
"      Pollock AV. Laparotomy. J R Soc Med 1981; 74:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/35\">",
"      Millbourn D, Cengiz Y, Israelsson LA. Effect of stitch length on wound complications after closure of midline incisions: a randomized controlled trial. Arch Surg 2009; 144:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/36\">",
"      Diener MK, Voss S, Jensen K, et al. Elective midline laparotomy closure: the INLINE systematic review and meta-analysis. Ann Surg 2010; 251:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/37\">",
"      PAREIRA MD, SERKES KD. Prediction of wound disruption by use of the healing ridge. Surg Gynecol Obstet 1962; 115:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/38\">",
"      Ceydeli A, Rucinski J, Wise L. Finding the best abdominal closure: an evidence-based review of the literature. Curr Surg 2005; 62:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/39\">",
"      Hubbard TB Jr, Rever WB Jr. Retention sutures in the closure of abdominal incisions. Am J Surg 1972; 124:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/40\">",
"      Rink AD, Goldschmidt D, Dietrich J, et al. Negative side-effects of retention sutures for abdominal wound closure. A prospective randomised study. Eur J Surg 2000; 166:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/41\">",
"      Gerten KA, Richter HE, Wheeler TL 2nd, et al. Intraabdominal pressure changes associated with lifting: implications for postoperative activity restrictions. Am J Obstet Gynecol 2008; 198:306.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/42\">",
"      Weir LF, Nygaard IE, Wilken J, et al. Postoperative activity restrictions: any evidence? Obstet Gynecol 2006; 107:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/43\">",
"      Greer BE, Cain JM, Figge DC, et al. Supraumbilical upper abdominal midline incision for pelvic surgery in the morbidly obese patient. Obstet Gynecol 1990; 76:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/44\">",
"      Krebs HB, Helmkamp BF. Transverse periumbilical incision in the massively obese patient. Obstet Gynecol 1984; 63:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/45\">",
"      Gallup DG. Modifications of celiotomy techniques to decrease morbidity in obese gynecologic patients. Am J Obstet Gynecol 1984; 150:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/46\">",
"      Morrow CP, Hernandez WL, Townsend DE, Disaia PJ. Pelvic celiotomy in the obese patient. Am J Obstet Gynecol 1977; 127:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/47\">",
"      TELOH HA, MASON ML, WHEELOCK MC. A histopathologic study of radiation injuries of the skin. Surg Gynecol Obstet 1950; 90:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/39/21113/abstract/48\">",
"      Hoffman MS, Villa A, Roberts WS, et al. Mass closure of the abdominal wound with delayed absorbable suture in surgery for gynecologic cancer. J Reprod Med 1991; 36:356.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21113=[""].join("\n");
var outline_f20_39_21113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H174061205\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEMATOMA AND SEROMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SURGICAL SITE INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H174061383\">",
"      - Incision and drainage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H174061366\">",
"      - Wound dressings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H174061372\">",
"      - Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H174061378\">",
"      - Delayed closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H174061904\">",
"      - Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H174062184\">",
"      - Surgical technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FASCIAL DEHISCENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Patient risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H573601170\">",
"      Technical factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Incisional factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Suture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H607392140\">",
"      - Lifting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H174061632\">",
"      NERVE INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SPECIAL SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Morbid obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Panniculectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H174061205\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/1\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/49/35603\" title=\"figure 1\">",
"      CDC SSI classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/48/3842\" title=\"figure 2A\">",
"      Through and through retention sutures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/55/3953\" title=\"figure 2B\">",
"      Vertical mattress retention sutures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/11/7346\" title=\"figure 2C\">",
"      Parallel retention sutures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/19/12594\" title=\"figure 2D\">",
"      Double retention sutures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/32/43521\" title=\"figure 3A\">",
"      Bookwalter retractor A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/10/21670\" title=\"figure 3B\">",
"      Bookwalter retractor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/53/2896\" title=\"figure 4\">",
"      Subumbilical incision in obese",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/59/14257\" title=\"figure 5\">",
"      Cephalad retraction panniculus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/28/30144\" title=\"figure 6\">",
"      Caudal retraction panniculus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/2/34861\" title=\"table 1\">",
"      Criteria for SSI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/21/13660\" title=\"table 2\">",
"      Risk factors for SSI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/53/32604\" title=\"table 3\">",
"      Properties of dressings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/31/17916\" title=\"table 4\">",
"      Best pract infection prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/46/23275\" title=\"table 5\">",
"      Timing of surgical prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/52/24397\" title=\"table 6\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/28/13771\" title=\"table 7\">",
"      Risk factors for dehiscence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=related_link\">",
"      Basic principles of wound management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37761?source=related_link\">",
"      Clinical microbiology review: Wound, skin, and soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9465?source=related_link\">",
"      Inguinal and femoral hernia repair: Open techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=related_link\">",
"      Nerve injury associated with pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33834?source=related_link\">",
"      Overview of complications occurring in the post-anesthesia care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=related_link\">",
"      Postoperative fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=related_link\">",
"      Principles of abdominal wall closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30265?source=related_link\">",
"      Principles of abdominal wall incisions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_39_21114="Netherton syndrome";
var content_f20_39_21114=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87481%7EDERM%2F87482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87481%7EDERM%2F87482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Netherton syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Short, sparse hair is present in this patient with Netherton syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Ichthyosis linearis circumflexa in Netherton syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serpiginous, erythematous, pruritic plaques with double-edged peripheral scale develop in patients with Netherton syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21114=[""].join("\n");
var outline_f20_39_21114=null;
var title_f20_39_21115="Asthma peak flow instruct";
var content_f20_39_21115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Asthma daily diary II instructions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       To do a peak flow measurement:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Take a deep breath, seal your lips around the mouthpiece, blow as hard and as quickly as you can (like blowing out a candle), check the number, re-set the pointer to zero and repeat.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Generally, the best of three peak flow values is the one to record on the chart.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Record the date at the top of the chart.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Use an",
"       <strong>",
"        <sup>",
"         o",
"        </sup>",
"       </strong>",
"       for first morning values.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Use a &bull; for afternoon or evening values.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Use a &Delta; for before exercise.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Use an",
"       <strong>",
"        x",
"       </strong>",
"       for after exercise or with symptoms.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; If your peak flow is lower than normal, check your action plan or call your asthma care provider.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Woolcock Institute of Medical Research, 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21115=[""].join("\n");
var outline_f20_39_21115=null;
var title_f20_39_21116="Postexposure prophylaxis hepatitis B vaccine";
var content_f20_39_21116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended postexposure prophylaxis for percutaneous or permucosal exposure to hepatitis B virus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Treatment when source is:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        HBsAg positive",
"       </td>",
"       <td class=\"subtitle2\">",
"        HBsAg negative",
"       </td>",
"       <td class=\"subtitle2\">",
"        Not tested or unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Vaccination and antibody response status of exposed person",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Unvaccinated",
"       </td>",
"       <td>",
"        HBIG x 1; initiate HB vaccine series",
"       </td>",
"       <td>",
"        Initiate HB vaccine series",
"       </td>",
"       <td>",
"        Initiate HB vaccine series",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Previously vaccinated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Known responder",
"       </td>",
"       <td>",
"        No treatment",
"       </td>",
"       <td>",
"        No treatment",
"       </td>",
"       <td>",
"        No treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Known non-responder",
"       </td>",
"       <td>",
"        HBIG x 2 or HBIG x 1 and initiate revaccination",
"       </td>",
"       <td>",
"        No treatment",
"       </td>",
"       <td>",
"        If known high-risk source, treat as if source were HBsAg positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\" rowspan=\"3\">",
"        Antibody response unknown",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Test exposed person for anti-HBs",
"       </td>",
"       <td class=\"sublist_other_start\" rowspan=\"3\">",
"        No treatment",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Test exposed person for anti-HBs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        If adequate*, no treatment",
"       </td>",
"       <td class=\"sublist1\">",
"        If adequate*, no treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        If inadequate*, HBIG x 1 and vaccine booster",
"       </td>",
"       <td class=\"sublist1\">",
"        If inadequate*, initiate revaccination",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    HBsAg: hepatitis B surface antigen; HBIG: hepatitis B immunoglobulin; HB vaccine series: hepatitis B vaccine; anti-HBs: antibody to hepatitis B surface antigen.",
"    <br>",
"     For dosing information see \"Hepatitis B immune globulin: Drug information\" and \"Hepatitis B vaccine: Drug information\".",
"     <div class=\"footnotes\">",
"      * Responder is defined a person with adequate levels of serum antibody to hepatitis B surface antigen (ie, &ge;10 mlU/mL); inadequate response to vaccination defined as serum anti-HBs &lt;10 mlU/mL.",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of David Weber, MD, MPH.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21116=[""].join("\n");
var outline_f20_39_21116=null;
var title_f20_39_21117="Ischemic stroke classification";
var content_f20_39_21117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathophysiologic ischemic stroke classification",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Large vessel atherothrombotic stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        More common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bifurcation of the common carotid artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Siphon portion of the common carotid artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Middle cerebral artery stem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intracranial vertebral arteries proximal to middle basilar artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Origin of the vertebral arteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Less common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Origin of the common carotid artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Posterior cerebral artery stem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Origin of the major branches of the basilar-vertebral arteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Origin of the branches of the anterior, middle, and posterior cerebral arteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Small vessel (lacunar) stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mechanism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lipohyalinotic occlusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Less frequently proximal atherothrombotic occlusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Least likely embolic occlusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Most common locations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Penetrating branches of the anterior, middle, and posterior cerebral and basilar arteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardioaortic embolic stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cardiac sources definite - antithrombotic therapy generally used",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Left atrial thrombus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Left ventricular thrombus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial fibrillation and paroxysmal atrial fibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sustained atrial flutter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recent myocardial infarction (within&nbsp;one month)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rheumatic mitral or aortic valve disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bioprosthetic and mechanical heart valve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic myocardial infarction with ejection fraction &lt;28 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Symptomatic heart failure with ejection fraction &lt;30 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dilated cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cardiac sources definite - anticoagulation hazardous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacterial endocarditis (exception nonbacterial)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial myxoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cardiac sources possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mitral annular calcification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patent foramen ovale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial septal aneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial septal aneurysm with patent foramen ovale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Left ventricular aneurysm without thrombus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Isolated left atrial smoke (no mitral stenosis or atrial fibrillation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mitral valve strands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Ascending aortic atheromatous disease (&gt;4 mm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        True unknown source embolic stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moyamoya",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Binswanger's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral mass",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21117=[""].join("\n");
var outline_f20_39_21117=null;
var title_f20_39_21118="Acute HCV clearance";
var content_f20_39_21118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Time course of acute HCV infection with recovery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 363px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Figure adapted from: the Centers for Disease Control and Prevention.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21118=[""].join("\n");
var outline_f20_39_21118=null;
var title_f20_39_21119="Fibrin polymerization";
var content_f20_39_21119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Model of fibrin polymerization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 510px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thrombin (factor IIa) binds to fibrinogen and cleaves fibrinopeptides A and B (FPA, FPB) to generate fibrin monomers consisting of one E region (open circle) and two D regions (closed circles). Adjacent monomers self-assemble to form protofibrils through interaction of complementary sites between the D and E regions (D-E contact). FPB release exposes additional determinants complementary with binding sites on the D region, resulting in lateral growth and thickening of the protofibrils. Factor XIIIa induces formation of covalent bonds between adjacent D regions (D-D contact, shown here as double lines) to stabilize the fibrin polymer. The exact spatial orientation of D-D cross-linking remains unresolved. There is evidence supporting both longitudinal as well as transverse cross-linking between adjacent D regions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_39_21119=[""].join("\n");
var outline_f20_39_21119=null;
